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I. INTRODUCTION
The Dust Bowl seemed to sweep down upon an unsuspecting
people from out of nowhere. Yet now, when we look back, we
wonder how we could have been so foolish as to allow the reckless
1
and ruthless plowing of so much of the Plains.
Today, U.S. livestock production relies heavily on antimicrobials,
hormones, and a variety of other pharmaceuticals. A number of
concerns have been raised about these developments, including the
presence of drug residues in meat and the impact of these production
techniques on animal welfare.
This article, however, focuses
particularly on an issue that has not received attention—the potential
environmental impact associated with this pervasive use of
pharmaceuticals. It questions whether our use of drugs in livestock
production, in combination with the concentration of production, can
be likened to farmers’ naïve plowing of the Plains in the 1930’s. Like

1. See generally TIMOTHY EGAN, THE WORST HARD TIME: THE UNTOLD STORY OF
THOSE WHO SURVIVED THE GREAT AMERICAN DUST BOWL (Anton Mueller ed., 2006)
(relating the problems of people who lived through the Great Depression’s dust bowl).
Appreciation is extended to Associate Dean Don Judges for his thoughts and inspiration
regarding the connections between the dust bowl disaster and issues of environmental
consequence today.
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those farmers, we have beneficially increased the volume of what we
produce. But is our dependence on animal drugs reckless and
ruthless when viewed in terms of the long-term environmental
consequences? Are we on our way to creating a new and different
ecological disaster? Will we look back and wonder how we could
have been so foolish?
This article will set the stage by providing an overview of the
U.S. livestock industry. It will emphasize how the industry has
changed in the last several decades, noting the intensification of
individual production facilities and the concentration of the industry
in certain regions. These changes have already had significant
environmental impacts and additional risks will present going
forward.
The article will proceed to examine the industry’s overall
dependence on pharmaceuticals. There may be a passionate young
movement toward antibiotic-free, hormone-free, and organic
production. Nevertheless, the industry standard and the vast majority
of the meat and poultry production in the United States still depends
on the use of antibiotics, hormones, beta-agonists, and other drugs
2
used to sustain production levels. These drugs, in particular the
antibiotics, enable intense confinement of animals in mega-facilities
3
that house thousands of hogs and tens of thousands of chickens. The
two billion animals that are raised in the United States each year
produce over 1 billion tons of manure—manure that contains residues
4
of many of the drugs these animals were given.
Following this examination, the article will describe the
regulatory process in place for the approval of animal drugs and
argue that this process is insufficient and ineffective. As will be
shown, more robust regulation faces significant impediments,
2. See Lauren Orrico, Squashing the Superbugs: A Proposed Multifaceted Approach to
Combatting Antibiotic-Resistant Bacteria, 27 J.L. & HEALTH 259, 263–64 (2014) (discussing that
“cramped conditions [on factory farms are] ripe for bacterial epidemics” and that as a result,
factory farms depend on antibiotics to combat “the spread of disease among animals kept in
close quarters”).
3. See id. (noting how animal feed containing antibiotics, hormones, and other materials
is used to maintain high concentrations of animals in small areas and in unsanitary conditions).]
4. See OCTAVIA CONERLY & LESLEY VAZQUEZ CORIANO, U.S. ENVTL. PROT.
AGENCY, EPA 820-R-13-002 LITERATURE REVIEW OF CONTAMINANTS IN LIVESTOCK AND
POULTRY MANURE AND IMPLICATIONS FOR WATER QUALITY 5 (2013), available at
http://water.epa.gov/scitech/cec/upload/Literature-Review-of-Contaminants-in-Livestock-andPoultry-Manure-and-Implications-for-Water-Quality.pdf (noting that the contaminants
associated with manure can enter the environment through storage, handling, and land
application).
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including Congressional support for drug use in the livestock industry.
This article concludes, that environmental advocates can confront
these headwinds with strategies for change—by reordering industry
priorities, increasing transparency, and reevaluating our means of
production. These strategies can help us to prevent another ecological
disaster.
II. OVERVIEW OF U.S. LIVESTOCK PRODUCTION
According to a recent U.S. Department of Agriculture (USDA}
Economic Research Service report, the livestock industry in the
United States has “undergone a series of striking transformations” in
5
recent decades. Fifty years ago, the majority of livestock were
produced on diversified independent farms—farms that were diverse
6
in both the types of livestock and the variety of crops raised. Today,
the majority of the livestock raised in the United States are produced
7
on large specialized farms.
Specialization in this context may mean not only that farms are
limited to a single species of animal, but that they raise that species
only during a single stage of its life. Large livestock operations
“increasingly specialize in a single stage of livestock production, such
8
as hog finishing,” with animals shifting from one specialized unit to
9
another throughout their life cycle. Specialization is further evident
in the careful breeding of one genetic line that meets processor
10
expectations.
There has also been a dramatic increase in the size of livestock
operations. We have more than doubled the number of livestock and
poultry produced, a figure that now exceeds over 2 billion head of
livestock per year. This development has coincided with an 80%
decrease in the number of farms. Most livestock and poultry are no

5. JAMES M. MACDONALD & WILLIAM D. MCBRIDE, U.S. DEP’T. AGRIC., ECON.
RESEARCH SERV., EIB- 43, THE TRANSFORMATION OF U.S. LIVESTOCK AGRICULTURE:
SCALE, EFFICIENCY, AND RISKS iii (2009), available at http://www.ers.usda.gov/
media/184977/eib43.pdf [hereinafter TRANSFORMATION].
6. JAMES M. MACDONALD ET AL., U.S. DEP’T. AGRIC., ECON. RESEARCH SERV., ERR152, FARM SIZE AND THE ORGANIZATION OF U.S. CROP FARMING 31 (2013), available at
http://www.ers.usda.gov/media/1156726/err152.pdf.
7. Id.
8. TRANSFORMATION, supra note 5, at 1.
9. See id. at 8 (explaining that most market hogs come from “feeder-to-finish” operations
that involves pigs cycling through all three stages of hog production).
10. See id. at 20 (noting that “controlling the genetics of their pigs and chicks” is one of the
ways that processors assure uniformity to maintain processing efficiencies).
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longer raised on pasture, but in confinement, allowing for greater
11
control over the animals and larger numbers of animals per facility.
The EPA’s definition of a “Concentrated Animal Feeding
Operation” (CAFO) for purposes of environmental regulation
represents an attempt to accurately characterize these changes in the
livestock industry. An “Animal Feeding Operation” (AFO) is
defined to be one where animals are confined and fed for 45 days or
12
more in any 12-month period without grazing or foraging access. A
CAFO is an AFO that has been designated as a point source for
water pollution under the Clean Water Act largely because of its size,
13
as measured by the number of animals in the facility. The concept,
as well as the regulatory definition of a CAFO, embodies the
dominant approach to livestock production today. A CAFO is “a
production process that concentrates large numbers of animals in
relatively small and confined spaces, and that substitutes structures
and equipment (for feeding, temperature controls, and manure
14
management) for land and labor.”
This “production process”—the transformed system of livestock
production in the United States—is not based solely on economies of
scale. One of the technologies integral to this transformation is the
15
16
use of drugs to enhance growth, alter the animals’ physiology, and
provide short-term disease prevention while animals are under
17
stress. This article will now look at current production practices
within four of the major livestock industries—the swine industry, the
poultry industry (focusing on broiler production), the dairy industry,
and the beef cattle industry—to set the stage for examining drug use
within these industries and the resulting environmental concerns.
A. The Swine Industry
As a USDA report from 2008 noted, “[t]oday’s hog sector bears
little resemblance to the one that existed 15 years ago . . . . There are
11. See id. at 1 (describing how livestock are fed in confined areas with automated feed
milling and delivery, grouped according to certain characteristics for feed formulas).
12. 40 C.F.R. § 122.23(b)(1)(i) (2014).
13. 40 C.F.R. § 122.23(b)(2).
14. TRANSFORMATION, supra note 5, at 3.
15. Id. at 32.
16. Alberto Alemanno & Giuseppe Capodieci, Testing the Limits of Global Food
Governance: The Case of Ractopamine, 3 EUR. J. OF RISK REG. 2 (2012) (describing
Ractopamine as causing an “increase muscle leanness by inducing a redistribution of fat to
muscle tissue in certain food animal species such as pigs and cattle”).
17. TRANSFORMATION, supra note 5, at 32.
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fewer hog farms, and the average number of hogs per farm has
18
In 1992, there were more than 240,000
increased substantially.”
farms that raised hogs. By 2004, less than 70,000 hog farms
remained—a drop of over 70 percent. Yet, the overall size of the U.S.
19
hog inventory “remained stable at about 60 million head.”
Data from the 2012 Agricultural Census confirms the continued
concentration of hog production on large farms. Hog and pig sales in
2012 totaled $4.4 billion, up 24.6 percent from the last census in
20
2007. However, “[e]ven as the value of sales went up, the number of
21
farms with hog and pig sales declined by 25 percent.” Farms that
22
specialized in hog production declined by 29%. The bottom line is
that more hogs are raised on fewer, larger specialized farms.
Large hog facilities present complex manure management
problems. Data from the 2007 census were used to estimate that the
hog industry alone generates over 111 million tons of manure per
23
year.
Swine are typically housed over slatted floors, allowing manure
to be washed down and routinely flushed out of the housing facility.
Swine manure may be flushed to an underground pit (57% of
operations), or another storage area like a manure pile (20% of
24
operations).
In addition to concentration into larger facilities, these hog farms
are now concentrated regionally. Regional concentration exacerbates
manure management problems as states contend with clusters of large
confinement facilities. Iowa, the top hog producing state, was
25
responsible for 27 percent of swine production in 2007. Iowa hogs
18. NIGEL KEY & WILLIAM D. MCBRIDE, U.S. DEP’T AGRIC., ECON. RESEARCH SERV.,
TECHNOLOGY, LARGER FARM SIZE INCREASED PRODUCTIVITY ON U.S. HOG FARMS 17,
AMBER WAVES (Apr. 2008), available at http://www.ers.usda.gov/amber-waves/2008april/technology,-larger-farm-size-increased-productivity-on-us-hogfarms.aspx#.VRLcu8ZX80k.
19. Id. at 18.
20. U.S. DEP’T. AGRIC., NAT’L AGRIC. STATISTICS SERV., ACH12–4, 2012 CENSUS
HIGHLIGHTS, HOG AND PIG FARMING 1 (2014), available at http://www.agcensus.usda.gov/
Publications/2012/Online_Resources/Highlights/Hog_and_Pig_Farming/#industry [hereinafter
HOG AND PIG FARMING].
21. Id.
22. Id.
23. CONERLY & CORIANO, supra note 4, at 7, tbl.2-2.
24. Id. at 9 (citing Richard.W. Gullick et al., AWWA RESEARCH FOUND. & UNITED
STATESENVTL. PROT. AGENCY., SOURCE WATER PROTECTION FOR CONCENTRATED
FEEDING OPERATIONS: A GUIDE FOR DRINKING WATER UTILITIES (2007), available at
http://waterrf.org/PublicReport Library/91159.pdf).
25. Id. at 7, tbl.2-2.
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26

and pigs produced over 31 million tons of manure that year. North
Carolina, the second-largest hog-producing state in the country,
raised 15.5% of U.S. swine, resulting in over 17 million tons of hog
27
manure. The third-ranked state, Minnesota, was responsible for just
over 11% of national production and contended with more than 12.7
28
million tons of hog manure in 2007 alone. Farms in these three
states alone “accounted for 55 percent of the value of U.S. hog and
pig sales and 56 percent of the 66 million hog and pig end-of-year
29
inventory in 2012.”
Unfortunately, concentration of production
leads to a concentration of waste outputs as well. This highlylocalized inundation of manure poses acute environmental risks.
B. The Poultry Industry
The poultry industry follows a similar pattern. The 2012 Census
of Agriculture reported that U.S. poultry and egg sales totaled $42.8
30
31
billion in 2012. This was a 15% increase since 2007. Yet, the
Census also showed that the number of farms with poultry and egg
32
sales decreased by 8%. Large, specialized farms accounted for 98%
33
($42.0 billion) of sales in 2012.
The poultry business can be divided into production categories,
with chicken production dwarfing the production of other fowl such
as turkey, ducks, quail, geese, and others. The 2012 Census of
Agriculture estimates the U.S. inventory of chickens at
34
1,506,300,000. In contrast, the turkey inventory was estimated to be
35
just over 100 million.
Chicken production can be further divided into subcategories
based on use: broilers and other chickens raised for meat, laying hens
(including both those raised to produce table eggs and those raised to
produce pullets for broiler production); and pullets (young chickens

26.
27.
28.
29.
30.

Id.
Id.
Id.
HOG AND PIG FARMING, supra note 20, at 1.
USDA, NAT’L AGRIC. STATISTICS SERV., ACH12–18, 2012 CENSUS HIGHLIGHTS,
POULTRY AND EGG PRODUCTION 1 (2015), available at http://www.agcensus.usda.gov/
Publications/2012/Online_Resources/Highlights/Poultry/Poultry_and_Egg_Production.pdf
[hereinafter POULTRY AND EGG PRODUCTION].
31. Id.
32. Id. at 2.
33. Id.
34. Id.
35. Id.
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36

raised to replace the layers).
A facility is typically designed to
37
accommodate only one of these categories.
1. Broiler Production
Broiler production is vertically integrated, with poultry
38
processors controlling all aspects of production. While diversified
farms of the previous generation had “chicken coops”—i.e., small
structures with access to a yard or run—in today’s commercial
chicken production, housing for a broiler’s short life is typically in a
20,000 square feet rectangular building that is approximately 40 feet
39
wide and 500 feet long.
A house this size is used to produce
115,000–135,000 birds in a year through confined growing conditions
40
and one-flock-after-another production. Farmers are encouraged to
41
build these houses in pairs, doubling annual production. Now, few
growers still produce fewer than 100,000 broilers per year. In fact, the
production locus has grown from 300,000 broilers in 1987 to 520,000
42
in 2002, to 600,000 by 2006.”
Poultry manure accumulates inside the broiler house, mixed with
43
whatever bedding is provided. Broiler chickens in the United States
44
produced over 52.7 million tons of manure in 2007.
Broiler production is concentrated along the Atlantic coast from
Delaware south to Georgia, and in the southern states of Alabama,
45
Mississippi, and Arkansas.
Three southeastern states lead the
nation—Georgia, with 14.7% of U.S. broilers, Arkansas, with 12.6%,
46
and Alabama, with 11.1%. As in the hog industry, this means a lot
of manure concentrated in a handful of states. In 2007, Georgia was
responsible for 7.7 million tons of manure, Arkansas for over 6.6
47
million tons, and Alabama for over 5.8 million tons.

36. Id.
37. Id.
38. TRANSFORMATION, supra note 5, at 6 fig.1.
39. Id. at 18.
40. Id.
41. Id. (referencing measurements from the 2006 ARMS broiler survey).
42. Id. at 7.
43. CONERLY & CORIANO, supra note 4, at 10.
44. Id. at 8.
45. Poultry & Eggs: Background, U.S. DEP’T. AGRIC., ECON. RESEARCH. SERV.,
http://www.ers.usda.gov/topics/animal-products/poultry-eggs/background.aspx (last updated
May 28, 2012).
46. CONERLY & CORIANO, supra note 4, at 8.
47. Id.
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2. Egg Production
The USDA National Agricultural Statistics Service estimates
48
that the U.S. egg industry produced over 95 billion eggs in 2013. The
most recent monthly report estimates that 8.63 billion eggs were
produced in the United States in December 2014 alone, an amount
49
that is up 3% from last year.
The egg industry has become very concentrated and operates
50
under a corporate model. According to the American Egg Board, in
1994, approximately 350 companies had layer flocks of 75,000 hens or
51
more.
Today, that number has declined to 175 companies with
52
However, these 175 companies
flocks of 75,000 hens or more.
53
“represent about 99 percent of all the hens in the United States.” Of
these, there are “approximately 66 egg producing companies with 1
54
million-plus hens.” These companies alone control approximately
87 percent of total production. Seventeen companies each have
55
greater than 5 million hens.
It is estimated that there were 306 million layers in the United
56
States at the end of 2014. Most layers are housed in elevated cages,
allowing manure to accumulate below or drop onto a conveyor belt
57
that removes manure from the building. Manure is typically washed
58
from the housing facility to a storage pit. Estimates of total manure
48. USDA NAT’L AGRIC. STATISTICS SERV., CHICKENS AND EGGS 2013 SUMMARY 7
(2014), available at http://usda.mannlib.cornell.edu/usda/nass/ChickEgg//2010s/ 2014/ChickEgg02-27-2014.pdf.
49. USDA NAT’L AGRIC. STATISTICS SERV., CHICKENS AND EGGS DECEMBER REPORT 4
(2015), available at http://usda.mannlib.cornell.edu/usda/nass/ChicEggs//2010s/2015/ChicEggs01-23-2015.pdf.
50. The American Egg Board is an organization funded through the congressionally
created “checkoff” program that assesses a charge from companies with more than 75,000 layer
chickens in the United States. Egg Research and Consumer Information Act, 7 U.S.C. §§ 2701–
2718 (2012). The AEB is run by a board that is appointed by the Secretary of Agriculture.
About AEB, AM. EGG BD., http://www.aeb.org/about-aeb/about (last visited Mar. 1, 2015).
51. Industry Overview, AMERICAN EGG BD., http://www.aeb.org/farmers-andmarketers/industry-overview (last visited Mar. 1, 2015) [hereinafter Industry Overview].
52. Id.
53. Id.
54. Id.
55. Id.
56. Id.
57. CONERLY & CORIANO, supra note 4, at 10 (citing RICHARD.W. GULLICK ET AL.,
AWWA RESEARCH FOUND. & UNITED STATES. ENVTL. PROT. AGENCY., SOURCE WATER
PROTECTION FOR CONCENTRATED FEEDING OPERATIONS: A GUIDE FOR DRINKING WATER
UTILITIES 1 (2007), available at http://waterrf.org/PublicReport Library/91159.pdf).
58. Id. (referencing Zhao et al., Hormones in Waste from Concentrated Animal Feeding
Operations, in FATE AND TRANSPORT OF PHARMACEUTICALS IN THE ENVIRONMENT AND
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production associated with egg production are difficult to find.
However, the USDA estimates that layer chickens produce
approximately 60.5 lbs. of manure per day per 1000 lbs. of animal
59
unit.
Like each of the previously discussed industries, egg
production is regionally concentrated. Five states—Iowa, Ohio,
Indiana, Pennsylvania, and Texas—represent approximately 51% of
60
all U.S. egg production, and thus find themselves responsible for a
majority of the nation’s chicken waste.
C. The Cattle and Dairy Industries
The beef cattle and dairy industries are obviously related; both
depend on cattle and both contribute to the supply of beef available
to consumers. They are, however, profoundly different in structure
and production methods.
1. The Dairy Industry
The dairy industry has also exhibited a dramatic transformation
with fewer farms and a production shift to farms that are significantly
larger in size. The 2012 Census of Agriculture estimates that there
61
were 9.3 million milk cows in the United States at the end of 2012.
This was down 0.2% from 2007, although the number of farms
62
involved declined by 8% during that time period.
This trend has been ongoing for some time. Between 1997 and
2007, dairy production remained relatively stable, while the number
63
of dairy farms in the United States dropped by nearly 50%. Recent
USDA estimates indicate that the number of dairy farms fell by
nearly 60% over the past 20 years, even as total milk production
64
increased by one-third.
The production locus or midpoint (the
measurement of the size of a farm at which half of production would
WATER TREATMENT SYSTEMS (Diana S. Aga, ed., 2008)).
59. Animal Manure Management, U.S. DEP’T AGRIC., NATURAL RES. CONSERVATION
SERV. (1995), http://www.nrcs.usda.gov/wps/portal/nrcs/detail//?cid=nrcs143_014211#table1.
60. Industry Overview, supra note 51.
61. USDA NAT’L. AGRIC. STATISTICS SERV., ACH12–14, 2012 CENSUS HIGHLIGHTS,
DAIRY CATTLE AND MILK PRODUCTION 1 (2014), available at http://www.agcensus.usda.gov/
Publications/2012/Online_Resources/Highlights/Dairy_Cattle_Milk_Prod/Dairy_Cattle_and_Mi
lk_Production_Highlights.pdf.
62. Id.
63. CONERLY & CORIANO, supra note 4, at 11.
64. James MacDonald & Doris Newton, Milk Production Continues Shifting to LargeScale Farms, U.S. DEP’T AGRIC., ECON. RESEARCH SERV. (Dec. 1, 2014),
http://www.ers.usda.gov/amber-waves/2014-december/milk-production-continues-shifting-tolarge-scale-farms.aspx#.VM7MOFXF-l1.
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come from larger farms and half from smaller) shifted dramatically
65
from 80 cows in 1987 to 275 by 2002. By 2012 it was 900 cows, and
66
“farms with at least 1,000 cows accounted for 49 percent of all cows.”
The large size and active metabolism of a lactating cow result in a
tremendous volume of associated waste. It is estimated that, on
average, a lactating dairy cow will generate 50 liters of manure,
67
The University of Wisconsin
including urine, every single day.
Agricultural Extension Service developed a chart for farmers to
compute manure production from their herd. For one average 1400
lb. dairy cow, the chart estimates that 21.9 tons of manure per year
68
will be produced.
Dairy production is concentrated in California and Wisconsin;
69
together these states account for a third of U.S. dairy sales. The top
70
Following
ten states account for nearly three-fourths of sales.
California and Wisconsin, these states, in order of production, are
New York, Idaho, Pennsylvania, Texas, Minnesota, Michigan, New
71
Mexico, and Washington.
2. The Beef Cattle Industry
The United States boasts “the world’s largest fed-cattle
72
industry,” and is also the “world’s largest producer of beef.” It is
known for its grain-fed beef for domestic and export markets.
Feedlots provide for “finishing” and preparing cattle for
slaughter. There, they are fed a high-energy ration that is 70–90%
73
grain and protein concentrate. They are usually in the feedlot for
74
about 140 days, with variations between 90 and 300 days reported.
Their average weight gain is 2.5–4 pounds per day based on 6 pounds
75
of feed per pound of gain.
65. TRANSFORMATION, supra note 5, at 5–6.
66. MacDonald & Newton, supra note 64.
67. CONERLY & CORIANO, supra note 4, at 5.
68. UNIV. OF WIS. EXTENSION SERV., HOW MUCH FERTILIZER DO YOUR ANIMALS
PRODUCE? 1, available at http://learningstore.uwex.edu/assets/pdfs/a3601.pdf (last visited March
2, 2015).
69. U.S. DEP’T AGRIC., NAT’L. AGRIC. STATISTICS SERV., supra note 61, at 1.
70. Id.
71. Id.
72. Cattle and Beef, Cattle Background, USDA ECON. RESEARCH SERV. (May 26, 2012),
http://www.ers.usda.gov/topics/animal-products/cattle-beef/background.aspx [hereinafter Cattle
and Beef].
73. Id.
74. Id.
75. Id.

11-Schneider_Final (Do Not Delete)

238

DUKE ENVIRONMENTAL LAW & POLICY FORUM

8/17/2015 5:20 PM

[Vol. XXV:227

Today, feedlots represent the concentrated and the
76
“industrialized stage” of the cattle sector. Again, however, this is a
change from prior production practices. Individual farms and small
local feedlots were the norm until at least the mid-1960s. “In 1964,
feedlots with capacities of less than 1,000 head handled over 60
77
percent of U.S. fed-cattle marketings.”
Since that time, there has been a marked shift of the industry
toward large commercial feedlots, particularly those located in the
Great Plains and the West. These feedlots house tens of thousands of
cattle at a time, purchase feed ingredients, maintain their own
feedmills, and “employ nutritionists, veterinarians, and sales and
78
management staff.”
Feedlots with capacity for 1,000 head or more now market
79
between 80 and 90% of fed cattle. Feedlots with capacity for 32,000
80
head or more sell approximately 40% of the fed cattle market. “The
largest feedlots can feed 100,000 cattle at a time. Some are owned by
meatpackers, some are part of larger diversified firms, and others are
specialized cattle feeding businesses, sometimes with a feed
81
production enterprise as well.”
D. Summary: Livestock Production Today
The U.S. livestock and poultry industry produces over 2 billion
82
animals per year.
Most of these animals are being raised in
conditions and in concentrations that are relatively novel, as the
83
industry has seen a rapid and dramatic transformation. Within just
the last fifty years, we have moved from production on diversified and
dispersed smaller farms to large-scale industrial-style production that
both concentrates animals in confined facilities, and that are
84
concentrated themselves in specific regions of the country. This can
be said with regard to each major category of livestock that we
85
produce.

76.
77.
78.
79.
80.
81.
82.
83.
84.
85.

TRANSFORMATION, supra note 5, at 12.
Id.
Id.
Cattle and Beef, supra note 72.
Id.
TRANSFORMATION, supra note 5, at 12.
CONERLY & CORIANO, supra note 4, at 1.
Id.
Id.
Id.
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Livestock and poultry produced in the United States generate
86
over one billion tons of manure each year. In reasonable quantities,
and applied to land appropriately, manure can improve soil quantity
87
and provide essential nutrients for plant growth. However, when
concentrated in large quantities, manure can also degrade surface
88
water quality, pollute the air, and spread disease. Most concerns
about concentrated livestock production and manure have focused on
phosphorus and nitrate contamination associated with manure runoff
and spills. Some, however, have also raised the alarm that the drugs
given to the livestock and present in the manure are another cause for
89
serious concern.
It is not the purpose of this article to criticize the shift in
90
agricultural production per se. Rather, this article argues that the
current use of livestock drugs—drugs that in many instances make
concentrated production feasible—raises serious environmental and
public health risks. The next section of this article will discuss how
these drugs are used and their capacity to impact the environment.
III. THE USE OF PHARMACEUTICALS IN LIVESTOCK PRODUCTION
The transformation of the livestock industry has been largely
driven by efforts to decrease production costs. Producing more meat
at a cheaper price has been the driving influence of a very competitive
industry.
New technologies both support and encourage this objective.
Technological innovations initially offer opportunities for expanded
production and reduced costs, but then become the norm, forcing all
91
producers to adapt or else compete at a price disadvantage.

86. Id. at 5.
87. Id.
88. See id. at 1 (identifying environmental problems caused by manure concentration).
89. Id.
90. This author has expressed that view previously. See, e.g., Susan A. Schneider,
Reconsidering the Industrialization of Agriculture, 26 J. ENVTL. L. & LITIG. 19 (2011) (arguing
that external costs associated with large scale industrial production systems should be
considered and challenging the efficiency of these systems when these costs are included).
Many others have raised persuasive, passionate arguments about the broader consequences of
industrial agriculture including its impact on rural communities, the environment, and the
welfare of the animals raised. See, e.g., Neil D. Hamilton, Essay – Food Democracy and the
Future of American Values, 9 DRAKE J. AGRIC. L. 9 (2004) (discussing the changes in
agriculture and the changes in the U.S. food system).
91. This phenomenon is referred to as the “technology treadmill.” See Susan A.
Schneider, FOOD, FARMING, AND SUSTAINABILITY: READINGS IN AGRICULTURAL LAW 19
(2011) (referencing the work of Willard Cochrane).
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Mechanical innovations have allowed producers to reduce labor costs,
while chemical innovations have created pesticides that have
92
decreased pest loss and increased crop yields.
Biological
innovations—including breeding animals for specialized traits and
using a variety of animal drugs—have had a dramatic impact on
livestock production, reducing costs and increasing the volume and
speed of production.
New technologies often reduce costs directly, by allowing more
meat and milk to be produced for a given amount of land, feed,
labor, and capital. But the new technologies also create economies
of scale, which reduce costs more for larger operations. As a
result, larger farms realize higher profits, on average, which
provides a strong incentive for operators to grow. In turn, lower
industry-wide farm costs lead to lower prices for farm commodities.
Lower prices can squeeze smaller farms with higher costs, causing
many to exit, grow, or explore niche markets for differentiated
products.93

Unfortunately, these new technologies often create new
problems, and the most common response has been the development
of an additional new technology to address the problem. For
example, the overuse of the pesticide Glyphosate (RoundUp) has
94
resulted in the development of resistant “super weeds.” In response,
farmers are increasing the quantities of Glyphosate used and are
95
using more virulent pesticides, as well. The seed/chemical industries
suggest new pesticide/genetic modification technologies, and so the
96
treadmill continues.
In livestock agriculture, animal science researchers have focused
on developing drugs to provide greater efficiencies and/or to address
the problems caused by industrial production. This has been a
97
lucrative market for the pharmaceutical industry.
92. Id.
93. TRANSFORMATION, supra note 5, at 2.
94. Neil D. Hamilton, Don't Repeat Mistakes That Led To Superweeds, DES MOINES REG.
(June 28, 2014), http://www.desmoinesregister.com/story/opinion/columnists/iowa-view/2014/
06/28/repeat-mistakes-led-superweeds/11652199/.
95. Id.
96. Id.
97. “The 2007 U.S. Census of Manufacturing reports that total U.S. revenues from
veterinary pharmaceuticals are over $5.41 billion.” Brian L. Buhr et al., Health Competition in
the Animal Health Industry, CHOICES, http://www.choicesmagazine.org/magazine/article.php?
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This article will next discuss the most common categories of
drugs used in livestock production and the extent of their use.
Throughout this discussion, however, only estimates are provided,
sometimes expressed within a relatively wide range. This is because
there is no publicly available accurate data for drug use in the
livestock industry. Moreover, such information is generally not even
available to the government agency that regulates its use. Most
livestock drugs are sold “over-the-counter” without a prescription.
On-farm reporting is not required; most drugs are available without
veterinary supervision; and both feed recipes and drug use may be
98
considered proprietary information by industry.
Pharmaceutical
companies are now required to provide the Food and Drug
Administration (FDA) with some data on the total sales of certain
antibiotics sold for use in food animals. However, this data does not
reveal the animal species related to the purchase; the geographic
region of use; the purpose of the use (whether for disease prevention,
99
treatment, or growth promotion); nor the actual use or dosage.
A. Antimicrobials
It is estimated that between 60 and 80% of all livestock and
poultry produced in the United States routinely receive
antimicrobials of one type or another, most often at “sub100
therapeutic” levels. The majority of this use is estimated to be for
article=164 (last visited Mar. 31, 2015).
98. See CONERLY & CORIANO, supra note 4, at 28 (discussing antimicrobials); Id. at 40
(discussing hormones); see also U. S. GOV’T ACCOUNTABILITY OFFICE, GAO-04-490,
ANTIBIOTIC RESISTANCE: FEDERAL AGENCIES NEED TO BETTER FOCUS EFFORTS TO
ADDRESS RISKS TO HUMANS FROM ANTIBIOTIC USE IN ANIMALS (2004) (calling upon the
USDA and the HHS to develop strategies for data collection on use in the livestock industry).
99. The FDA recently proposed a rule that would take a first step to collect additional
data. The rule would require animal drug manufacturers to track the sale of antibiotics by
particular species, allowing FDA to determine which are sold for use in chicken, cattle, pigs,
turkeys, and other food-producing animal production. The rule would not reveal specific onfarm usage. Antimicrobial Animal Drug Sales and Distribution Reporting, 80 Fed. Reg. 28,863
(proposed May 20, 2015) (to be codified at 21 C.F.R. pt. 514); see also ANTIBIOTIC USE IN
ANIMALS, GAO-04-490 at 92 (FDA response to GAO recommendation that more data on
usage should be sought and maintained).
100. This refers to a dosage that would generally be insufficient for medicinal therapy to
treat an active infection but that provides other benefits to production, e.g., growth promotion
and possible disease prevention. While this term has been used extensively, the FDA now
prefers the term “production use” as it views the terms “nontherapeutic” and “subtherapeutic”
as “terms that we believe lack sufficient clarity.” FOOD & DRUG ADMIN., GUIDANCE FOR
INDUSTRY: THE JUDICIOUS USE OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS IN
FOOD-PRODUCING ANIMALS 4 n.3 (Apr. 13, 2012), available at http://www.fda.gov/
downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM21
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the purpose of enhancing growth and increasing feed conversion
101
In 2010, over 29 million
ratios rather than for medicinal reasons.
pounds of antimicrobials were sold for livestock production use, an
amount that is estimated to be “3–4 times the amount used by
102
humans.”
Ninety percent of these antimicrobials are estimated to
be delivered through the animals’ feed or water, and so provided to
103
all of the animals at once, en masse.
The routine use of antibiotics in livestock and poultry production
has been increasingly controversial, as the connection between
overuse in the livestock industry and the development of antibiotic
104
resistance has been confirmed. Antibiotic resistance is considered
to be one of the major public health concerns worldwide. According
to the World Health Organization, “[a]ntimicrobial resistance (AMR)
threatens the effective prevention and treatment of an everexpanding range of infections caused by bacteria, parasites, viruses,
and fungi. It is an increasingly serious threat to global public health
105
that requires action across all government sectors and society.” The
connection between agricultural use of antibiotics and antibiotic
resistance was first publically acknowledged in the landmark Report
of the Joint Committee on the Use of Antibiotics in Animal Husbandry
and Veterinary Medicine, more commonly known as the Swann
106
Report, published in Great Britain in 1969. This Report concluded
that “the administration of antibiotics to farm livestock, particularly
at sub-therapeutic levels, poses certain hazards to human and animal
health;” and that it has led to resistant bacteria that can be transfered
107
from animals to man.
6936.pdf [hereinafter JUDICIOUS USE].
101. CONERLY & CORIANO, supra note 4, at 27.
102. Id.
103. Meghan F. Davis & Lainie Rutkow, Regulatory Strategies to Combat Antimicrobial
Resistance of Animal Origin: Recommendations For a Science-Based Approach, 25 TUL. ENVTL.
L.J. 327, 331 (2012).
104. See JUDICIOUS USE, supra note 100, at 4 (finding that antimicrobial resistance is a
“public health problem of global significance”).
105. Antibiotic Resistance, WORLD HEALTH ORG. (Apr. 2014), http://www.who.int/
mediacentre/factsheets/fs194/en/.
106. M.M. SWANN, ET AL., REPORT OF THE JOINT COMMITTEE ON THE USE OF
ANTIBIOTICS IN ANIMAL HUSBANDRY AND VETERINARY MEDICINE, HMSO, London (1969).
This Joint Committee was appointed by the Health and Agriculture Ministers in Great Britain
in July 1968, and it was chaired by Professor M. M. Swann. The committee’s report was issued
in November 1969. Its findings are still cited today, and they formed the basis for the eventual
withdrawal of the approval for livestock use of many antimicrobials throughout Europe.
107. House of Lords, Session 1997-98, Science and Technology Committee Reports:
Science and Technology--Seventh Report, Ch. 3 Prudent Use In Animals, available at
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In the United States, there has been a series of research studies
and commission reports that have warned about the connections
between antibiotic use in livestock production and antibiotic
108
resistance.
While there are clearly other causes of resistance, the
link between the extensive use of antimicrobials in the livestock
industry and the development of antibiotic resistance with respect to
109
the specific drugs used, cannot reasonably be disputed.
For
example, in 2014, the President’s Council of Advisors on Science and
Technology confirmed the link in its report to President Obama.
Since retail meat can be a source of microbes, those antibioticresistant microbes can be transmitted to consumers. Even more
alarming is the fact that “antibiotic resistance can spread between
microbes (through the transfer of DNA elements, such as plasmids,
between species) and antibiotic-resistant microbes can spread from
animals to people who come into contact or close proximity with
110
them.”
Nevertheless, the extensive use of antibiotics continues today in
the livestock industry. Recent FDA data shows an increase rather
than a decrease in usage. In September of 2014, the FDA issued its
2012 summary report on the volume of antimicrobials sold for use in
livestock. It revealed that from 2009 to 2012, “[t]he total quantity of
antimicrobial active ingredients sold or distributed for use in food111
producing animals increased by 16%.” It is estimated that as many
http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ldsctech/081vii/st07
06.htm. It is telling to note that some of the specific antibiotics singled out by the Swann Report
as “unsuitable” for animal use in 1969 are still in use today in livestock production in the United
States.
108. See, e.g., JENNY LI & DAVID WALLINGA, INST. FOR AGRIC. AND TRADE POL’Y, NO
TIME TO LOSE: 147 STUDIES SUPPORTING PUBLIC HEALTH ACTION TO REDUCE ANTIBIOTIC
OVERUSE
IN
FOOD
ANIMALS
(2012),
available
at
http://www.iatp.org/files/
2012_11_08_AntibioticsBiliography_DW_JL_long_hyperlinks.pdf (describing the public health
risks associated with antibiotic use in livestock production and providing a bibliography of
studies documenting this risk).
109. See JUDICIOUS USE, supra note 100, at 5–17 (describing the link between the use of
antimicrobials in livestock and the development of antibiotic resistance). For a cogent
explanation for how antibiotic resistance can stem from the use of antibiotics in livestock
production, see Davis & Rutkow, supra note 103, at 335–37.
110. PRESIDENT’S COUNCIL OF ADVISORS ON SCIENCE AND TECHNOLOGY, REPORT TO
THE PRESIDENT ON COMBATTING ANTIBIOTIC RESISTANCE, 50–51 (Sept. 2014), available at
https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_amr_sept_2014_fin
al.pdf.
111. FOOD & DRUG ADMIN., DEPT. OF HEALTH & HUMAN SERV., 2012 SUMMARY
REPORT ON ANTIMICROBIALS SOLD OR DISTRIBUTED FOR USE IN FOOD-PRODUCING
ANIMALS 5 (Sept. 2014), available at http://www.fda.gov/downloads/ForIndustry/UserFees/
AnimalDrugUserFeeActADUFA/ UCM416983.pdf.
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as 55% of the types of antibiotic compounds used in the industry are
112
also used to treat human infections.
The resulting environmental impact of this antibiotic use is
significant. There are many pathogens that are associated with
livestock production; some are only adapted for a particular animal
species host, and others, termed zoonotic pathogens, are adapted to
113
produce infections in humans.
Some of these pathogens can be
114
extremely dangerous, even aside from antibiotic resistance. For all
of these pathogens, though, antibiotic resistance complicates
115
treatment and raises additional dangers.
These antibiotic resistant pathogens can be found on the
livestock, in their surroundings, and on the meat that is marketed to
consumers; thus, it can be spread to those in contact with the animals,
116
their surroundings, or their meat.
Both the pathogens and the
117
antimicrobials are found in the manure that is excreted. According
to EPA:
Antimicrobials are often only partially metabolized in livestock and
poultry and can be excreted virtually unchanged as the parent
compound. For example, up to 80% of tetracyclines may be
excreted by swine and poultry as the parent compound.
Additionally, up to 67% of the macrolide tylosin, which is
approved for use in beef cattle, dairy cows, swine, and poultry may
be excreted by livestock and poultry when the antimicrobial is
administered orally.118

After excretion, the antibiotics interact with the environment
when the manure is applied to land, carried in runoff, or associated

112. CONERLY & CORIANO, supra note 4, at 27.
113. Id. at 13.
114. See, e.g., Shiga Toxin-Producing Escherichia coli, 76 Fed. Reg. 58,157 (Sept. 20, 2011)
(announcing the USDA Food Safety and Inspection Service’s decision to declare certain Shiga
toxin-producing E. coli (STEC) as adulterants in non-intact raw beef products because of the
seriousness of the illnesses caused).
115. Antibiotic / Antimicrobial Resistance, CTR. FOR DISEASE CONTROL (Sept. 16, 2013),
http://www.cdc.gov/drugresistance/about.html.
116. Id.; see also The Trouble with Antibiotics (PBS Television Broadcast Oct. 14, 2014),
available at http://www.pbs.org/wgbh/pages/frontline/trouble-with-antibiotics/ (presenting
evidence of antibiotic resistant bacteria on meat and the genetic linking of the pathogens to
specific infections in humans).
117. CONERLY & CORIANO, supra note 4, at 35.
118. Id.
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119

with a spill. The occurrence of antimicrobials in soil, surface water,
and ground water has been well documented, with “antimicrobial
compounds present in 67 percent of ground water and surface water
samples collected near poultry operations and 31 percent of ground
120
water and surface water sample collected near swine operations.”
Because food-producing animals excrete 75% of the antimicrobials
they consume unchanged or as active metabolites of the drug,
antimicrobials not only apply selective pressure on the intestinal
microbial community of the food-producing animal, but also on the
microbiome of the animal's environment, such as the barn, pasture,
and fields where manure is applied. Spillage of medicated feed
may contaminate local soils and waters.
The presence of
antimicrobial drugs from these sources can influence the local
microbial ecology, allowing resistant organisms to survive and to
become more common in bacterial communities in and around
concentrated animal feeding operations (CAFOs). Further, the
CAFO environment, marked by crowding of animals in small,
often indoor spaces, intensifies the spread of bacteria among
animals and increases pathogen contamination of their barns or
pens . . . . Residents of rural communities may be exposed to
antimicrobial pollution through air and water contaminated by
manure waste, and consumers nationwide (and globally) can be
exposed through the retail meat, seafood, or other products they
contact, such as fertilizer derived from contaminated animal
products.121

A very recently published study confirms the transmission of
antibiotics, bacteria, and antibiotic-resistant genetic materials by
wind. The study tested areas surrounding commercial feedlots. The
study found these substances not only at sites a distance from the
feedlot, but also at greater levels downwind than upwind from the
122
feedlot, confirming wind transmission.
119. Id.
120. Id. at 36 (citing E.R. Campgnolo et al., Antimicrobial Residues in Animal Waste and
Water Resources Proximal to Large-Scale Swine and Poultry Feeding Operations, THE SCIENCE
OF THE TOTAL ENVIRONMENT 299: 89-95 (2002)).
121. Davis & Rutkow, supra note 103, at 339–40.
122. ANDREW D. MCEACHRAN ET AL., ENVTL. HEALTH PERSPECTIVES, ANTIBIOTICS,
BACTERIA, AND ANTIBIOTIC RESISTANCE GENES: AERIAL TRANSPORT FROM CATTLE FEED
YARDS VIA PARTICULATE MATTER (Jan. 22, 2015), available at http://ehp.niehs.nih.gov/wpcontent/uploads/advpub/2015/1/ehp.1408555.acco.pdf.
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Public health professionals around the world have been
expressing grave concerns about antibiotic resistance for some time.
Yet, in the United States, we are only beginning to appreciate the
significance of the environmental and public health threats posed by
using so many antibiotics in our livestock industry. It is time we
acknowledge the risks we have created.
B. Hormones
Hormones are produced naturally by animals, and the levels and
kinds of hormones produced will be impacted by a variety of factors
including growth, reproduction, other natural biological rhythms, and
stress. Some of the most ubiquitous hormones, produced throughout
life, include estrogen, progesterone, and testosterone. These natural
hormones are “necessary for normal development, growth, and
123
reproduction.”
A variety of steroid hormone drugs that supplement natural
production have been approved for use in beef cattle and sheep since
124
the 1950s.
These approved drugs include estrogen, progesterone,
125
and testosterone in natural and synthetic versions. These drugs are
given to animals to increase their growth rate, to increase feed
conversion ratios (the rate by which the animal converts feed to
weight gain for meat production), to improve meat quality, and to
126
affect reproduction.
According to the FDA, these drugs are typically administered in
cattle and sheep as “pellets that are placed under the skin on the back
127
side of the animal’s ear. The pellets dissolve slowly under the skin.”
Typical cattle implants contain trenbolone acetate and estradiol
128
benzoate. The FDA has not approved the use of exogenous steroid
129
hormones in swine, poultry, veal calves, or dairy cows.
In addition to the pellet delivery system, beef cattle on feedlots
may also receive daily doses of synthetic hormones (melengestrol
123. FOOD & DRUG ADMIN., Steroid Hormone Implants Used for Growth in FoodProducing (Oct. 14, 2014), http://www.fda.gov/AnimalVeterinary/SafetyHealth/ProductSafety
Information/ucm055436.htm [hereinafter Steroid Hormone Implants].
124. 21 C.F.R. §§ 522, 556, 558 (2014); Steroid Hormone Implants, supra note 123;
CONERLY & CORIANO, supra note 4 at 40–41.
125. Id.
126. Id.
127. Steroid Hormone Implants, supra note 123.
128. CONERLY & CORIANO, supra note 4, at 40.
129. See Steroid Hormone Implants, supra note 123 (“No steroid hormones are approved
for growth purposes in dairy cattle, veal calves, pigs, or poultry.”).
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130

acetate) in their feed.
Dairy cows often receive “intravaginal
controlled internal drug release (CIDR) inserts” of progesterone “to
control estrous (menstrual cycle), or to treat anestrous (non131
menstruating) females and females with cystic ovaries.”
Dairy cows may receive the genetically engineered hormone,
recombinant bovine somatotropin (rBST), often referred to as
recombinant bovine growth hormone (rBGH), to increase milk
132
production.
There are no public reports on the use of rBGH in
dairy production as reporting is not required. Consumer demand has
led to a vibrant market for “rBGH free” milk despite a skeptical
FDA, and labeling rules that generally mandate a disclaimer that
states that “[n]o significant difference has been shown between milk
133
derived from rBST-treated and non-rBST-treated cows.”
According to the FDA, “[a]ll of the steroid hormone growthpromoting drugs are available for over-the-counter purchase in the
United States and are generally given by the livestock producer at
134
specific stages of the animals’ growth.”
Because these drugs are
available for direct purchase, and because there are no USDA or
FDA reporting requirements, the full extent of hormone use in U.S.
livestock is not known.
USDA surveys can provide a window into common practices,
however. One survey reported that “[a]pproximately 39% of steers
and heifers weighing less than 700 pounds and 82% of those weighing
700 pounds or more received at least one hormonal implant in
135
1999.”
Larger livestock operations (8,000 cattle or more) were
136
more likely to use hormone implants than smaller operations.
Another survey reported that approximately 33% of dairy operations
137
used CIDR inserts in 2007.
A 2007 Dairy Survey reported that
“rBGH is the most common production enhancement injection used

130. CONERLY & CORIANO, supra note 4, at 40.
131. Id.
132. See Interim Guidance on the Voluntary Labeling of Milk and Milk Products From
Cows That Have Not Been Treated With Recombinant Bovine Somatotropin, 59 Fed. Reg.
6279, 6279 (Feb. 10, 1994) (stating that lactating dairy cows are given rBST to “increase the
production of marketable milk”).
133. Id. at 6280. Note, that the “no significant difference” claim was called into question in
the case of Int’l Dairy Foods Assoc. v. Boggs, 622 F.3d 628, 637 (6th Cir. 2010).
134. Id.; see also CONERLY & CORIANO, supra note 4, at 39 (stating that natural and
synthetic hormones are administered to cattle to promote growth).
135. CONERLY & CORIANO, supra note 4, at 40.
136. Id.
137. Id.
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138

in dairy operations.”
It is impossible to measure the total amounts of hormones
excreted in the manure produced in the livestock industry. However,
one well-regarded estimate indicates that in the year 2000 alone,
722,852 pounds of estrogens, androgens, and progestogens—not
139
including synthetic versions of these hormones—were excreted.
Although there is some indication that manure storage prior to land
application may allow hormones to degrade to inactive levels,
research indicates that many hormones are active even at low levels
140
and can still be considered endocrine disruptors.
C. Beta-agonists: Ractopamine and Zilmax
A third category of pharmaceutical, beta agonists, has been
introduced more recently to the livestock industry. This category of
drugs affects animals’ metabolic systems, shifting dietary energy
141
toward muscle growth as opposed to fat deposition.
It promises
142
faster growth and faster muscle mass accumulation.
Ractopamine is a beta agonist that has been approved for use in
143
medicated feed for swine since 1999.
It was approved for use in
144
145
cattle in 2003 and turkeys in 2008.
It is now estimated that 60–
80% of hogs produced in the United States are given ractopamine in
feed, often in combination with antibiotics such as Tylosin and
146
Monensin. Its use in turkeys and cattle is thought to be extensive,
but no public data is available for confirmation. In 2013, Merck
estimated that approximately 70% of U.S. beef cattle received either
138. Id.
139. Id. at 41.
140. See id. at 45 (“[w]hile hormones are typically detected at low concentrations, such
chemicals are biologically active at low levels and are classified as endocrine disruptors”).
141. See Donald H. Beerman et al., Council for Agric. Sci. & Tech., Animal Agriculture’s
Future Though Biotechnology Part 3: Metabolic Modifiers For Use In Animal Production, 30
ISSUE PAPER 1 (July 2005), available at http://www.cast-science.org/download.cfm?Publication
ID=2911&File=f0304b7365a7496a189a30694d7f4b617c4f
(“[t]hese
commercial
products
enhance carcass lean content and feed efficiency”).
142. See id. at 5 (stating that beta agonists stimulate muscle growth).
143. See generally 65 Fed. Reg. 4111 (Jan. 26, 2000) (final rule announcing the approval of
ractopamine hydrocholoride for use in swine feed and announcing the tolerance level for
residues of ractopamine in edible tissues of treated swine). This final rule indicates that the
drug was approved for use as of December 22, 1999 “for approved feed efficiency and increased
carcass leaness.” Id. at 4111.
144. Approved as Optaflexx.
145. Approved as Topmax.
146. See 21 C.F.R. § 558.500 (2014) (listing acceptable combinations of ractopamine,
Tylosin, and Monensin).
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Optaflexx, Eli Lilly’s brand of ractopamine in their feed, or Zilmax (a
147
competing beta agonist).
Ractopamine use is controversial. All countries in the European
Union, Russia, Taiwan and China have severely limited or restricted
ractopamine, citing food safety concerns; although it is allowed in the
148
United States, Canada, and Brazil.
European Union concerns
include very limited testing of effects on humans and reports of
adverse human reactions to the drug, including restlessness, anxiety,
149
and a fast heart rate. The U.S. pork industry, however, argues that
ractopamine is safe and that countries that have banned its use are
150
merely protecting their domestic pork industry.
There is no mandatory withdrawal period in the United States
for ractopamine, meaning animals can receive it up to slaughter with
a tolerance level expressed as the maximum residue limit (MRLs) of
151
50 ppb for pork and 30 ppb for beef. In 2012, Codex Alimentarius
152
Commission adopted a 10 ppb MRL for both beef and pork.
A
2012 study conducted by Consumer Reports tested 240 pork samples
and found that about 20% of samples were positive for low levels of
the drug, but the levels were reported to be below both the United
153
States and Codex MRLs.
Animal welfare concerns have been widely raised. In 2002, the
FDA Center for Veterinary Medicine Office of Surveillance and
Compliance accused Elanco (a division of Eli Lilly) of withholding
information about reports of “adverse animal drug experiences” and
154
the “safety and effectiveness” of the drug.
A warning label was
147. Kelsey Gee, Merck Suspends Sales of Cattle-Feed Additive Zilmax in U.S., Canada,
WALL ST. J. (Aug. 16, 2013), http://www.wsj.com/articles/SB10001424127887324139
404579016654038679072.
148. See Helena Bottemiller, FDA Petitioned to Lower Ractopamine Limits for Meat,
Review Health Impacts, FOOD SAFETY NEWS (Dec. 21, 2012), http://www.foodsafetynews.com/
2012/12/fda-petitioned-to-lower-ractopamine-limits-for-meat-review-animal-healthimpact/#.VNeFRFPF-l0 (describing different countries’ approaches to regulating ractopamine).
149. What’s in that pork?, CONSUMER REPORTS MAGAZINE (Jan, 2013)
http://www.consumerreports.org/cro/magazine/2013/01/what-s-in-that-pork/index.htm.
150. Id.
151. 21 U.S.C. § 556.570 (2014).
152. Helena Bottemiller, Codex Adopts Ractopamine Limits for Beef and Pork, FOOD
SAFETY NEWS (July 6, 2012), http://www.foodsafetynews.com/2012/07/codex-votes-69-67-toadvance-ractopamine-limits-for-beef-and-pork/#.VPcj0PnF98E.
153. Id.
154. Warning Letter from Gloria J. Dunnavan, Director, Division of Compliance, Center
for Veterinary Medicine, Office of Surveillance and Compliance, Food and Drug
Administration, to Patrick C. James, President Elanco Animal Health, A Division of Eli Lilly
and Company (Sept. 12, 2002) (on file with author).
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mandated, stating that “Ractomapine may increase the number of
155
injured and/or fatigued pigs during marketing.”
Opponents claim that ractopamine has been the subject of more
adverse report incidents in pigs than any other animal drug on the
market, citing reports to the FDA that include “trembling, lameness,
inability to walk or rise, reluctance to move, stiffness, hyperactivity,
156
hoof disorder, difficulty breathing, collapse, and death.” Pigs that
were administered ractopamine in a research barn squealed when
they took steps, as if in pain, and refused to leave their pens despite
proper handling; the pain was even more noticeable when they were
157
being shipped.
The debate over ractopamine is heightened due to the dramatic
problems associated with the competing beta agonist, Zilmax,
manufactured by Merck and approved for use in cattle since 2007.
Zilmax contains a different active ingredient, zilpaterol
hydrochloride, and is approved for use in commercial feedlots with a
158
withdrawal period of 3 days prior to slaughter.
The economic advantages of using Zilmax are enticing to the
industry. Merck’s Zilmax website promises gains “from 24 to 33
159
pounds of additional carcass weight” per animal.
Accordingly,
Merck reported $159 million in Zilmax sales in the United States and
Canada in 2012. Estimates are that Zilmax was fed to more than 25
million cattle. Significant animal health problems were reported, and
these reports culminated with the shocking presentation of cattle for
slaughter at a Tyson Plant in Washington. “[H]eifers and steers
hobbled down the ramps on August 5, barely able to walk. The
160
reason: The animals had lost their hooves.”
The common factor
among all of the animals was that they had been fed Merck & Co
161
Inc’s feed additive, Zilmax.
155. 21 C.F.R. 558.500 (2014); see also 67 Fed. Reg. 71,820 (Dec. 3, 2002) (providing notice
of the new labeling requirement).
156. Complaint at 9, Ctr. for Food Safety et al. v. Margaret A. Hamburg et al., No. 3:14-cv4932 (N.D. Cal. Nov. 6, 2014), available at http://www.biologicaldiversity.org/campaigns/
toxics_and_endangered_species/pdfs/2014-11-6_Ractopamine_Complaint.pdf.
157. Id.
158. 21 C.F.R. § 558.665 (2014).
159. Zilmax
Information
Center,
MERCK,
http://www.merck-animal-healthusa.com/products/zilmax/overview.aspx (last visited Mar. 25, 2015).
160. P.J. Huffstutter & Tom Polansek, Special Report: Lost Hooves, Dead Cattle Before
Merck
Halted
Zilmax
Sales,
REUTERS
(Dec.
30,
2013,
5:19
PM),
http://www.reuters.com/article/2013/12/30/us-zilmax-merck-cattle-special-reportidUSBRE9BT0NV20131230 [hereinafter Lost Hooves].
161. Id.
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The day after the hoofless animals were euthanized on August 6,
Tyson told its feedlot customers it would stop accepting Zilmax-fed
cattle. After Reuters reported the existence of a videotape of
apparently lame Zilmax-fed animals, Merck itself temporarily
suspended sales of the drug in the United States and Canada. The
rest of the nation’s leading meatpackers soon followed Tyson, the
largest U.S. meat processor.162

The FDA did not take any adverse action with regard to
Zilmax’s approval status.
Its active ingredient, zipaterol
163
hydrocholoride remains an approved animal drug for use in feed,
and Zilmax’s new drug application and approval is still available on
164
Merck is currently
the FDA’s website per its prior approval.
165
seeking to re-launch Zilmax at a lower dosage. The FDA approved
Merck’s Supplemental New Drug Application in October 2014
providing for a lower dosage of Zilmax to be sold for use in cattle fed
166
in confinement for slaughter.
Merck is currently working to
167
convince a still-skeptical beef industry that it should resume use.
Meanwhile, use of competing ractopamine products in the cattle

162. Id.; see also, Kelsey Gee, Merck Suspends Sales of Cattle-Feed Additive Zilmax in U.S.,
Canada, WALL ST. J. (Aug. 16, 2013, 12:01 PM), http://www.wsj.com/articles/SB100014
24127887324139404579016654038679072 (detailing Merck’s decision to suspend its sales of feed
with the Zilmax additive).
163. 21 C.F.R. § 558.665 (2014).
164. FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY, ORIGINAL NEW
ANIMAL DRUG APPLICATION NADA 141-258 41 (2006) (approving Zilmax as “safe and
effective”); see also ZILMAX, http://www.zilmax.com (last visited Feb. 24, 2015) (stating that
“Zilmax is an FDA-approved feed supplement.”).
165. P.J. Huffstutter & Tom Polansek, Exclusive: Merck Funds Tests of Lower Zilmax
Doses As Seen Seeking Way to Resume Sales, REUTERS (Jan. 19, 2015, 8:02 AM), http://www.
reuters.com/article/2015/01/19/us-merck-co-zilmax-idUSKBN0KS18020150119
[hereinafter
Merck Funds].
166. FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY, SUPPLEMENTAL
NEW
ANIMAL
DRUG
APPLICATION
NADA
141-258
(2014),
available
at
http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FO
IADrugSummaries/UCM421907.pdf (requiring adding the statement “CAUTION: Not to be
fed to cattle in excess of 90 mg/head/day”).
167. See Merck Funds, supra note 165(describing Merck’s efforts to resume sales of
Zilmax); see also Dan Charles, Beef Packers Block Plan To Revive Growth-Promoting Drug,
NATIONAL
PUBLIC
RADIO:
THE
SALT
(Jan.
27,
2015,
11:30
AM),
http://www.npr.org/blogs/thesalt/2015/01/27/381630528/beef-packers-block-plan-to-revivegrowth-promoting-drug (stating that Merck has been working on a plan to revive th use of
Zilmax).
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168

industry has soared.
Little is known about the exact amount of beta agonists that are
released into the environment from their use in the livestock industry,
or about their potential impact. As an example of an industry
assessment, in 1998 Elanco prepared an Environmental Assessment
(EA) in conjunction with their application for approval of their
169
ractopamine product for cattle. This assessment confirms that the
drug has the potential to impact the area surrounding the mixing
facilities; the feedlot area and its surroundings; agricultural lands
where manure is applied; and aquatic systems receiving runoff from
170
animal waste storage.
The EA grossly underestimates the actual
use of the drug, however, by referencing an “optimistic market
171
penetration rate of 35 percent.” Actual market penetration is now
172
estimated to be between 60–80%. The EA also describes a “typical
feedlot” as one housing 200 cows, when today’s feedlots typically hold
173
1,000-100,000 cattle at a time. In addition, the EA fails to consider
174
the cumulative impact of use in multiple species.
By some
estimates, “the combined population of ractopamine-drugged pigs,
175
cattle, and turkeys may excrete over a million pounds of the drug.”
The EA also fails to consider the impact of multiple drugs released
into the system as a result of competing drugs (e.g., ractopamine and
Zilmax).
D. Environmental Effects
The potential dangers of animal drugs in manure has already
been realized in the case of arsenic. Despite decades of prohibition of

168. See Jesse Newman, Merck Pushes to Revive Beef Drug, WALL ST. J. (July 14, 2014, 7:32
PM), http://www.wsj.com/articles/merck-pushes-to-revive-beef-drug-1405380749 (describing two
competitors’ entrance into the growth-promoting drug market).
169. ELANCO ANIMAL HEALTH, ENVIRONMENTAL ASSESSMENT FOR THE USE OF
RACTOPAMINE HYDROCHLORIDE PREMIX IN THE FEED OF CATTLE (1998), available at
http://www.fda.gov/downloads/AnimalVeterinary/DevelopmentApprovalProcess/Environmenta
lAssessments/UCM303565.pdf.
170. See id. at 5 (describing potential environmental impacts of the drug).
171. Id. at 9.
172. Complaint for Declaratory and Injunctive Relief at 16, Humane Soc’y of the U.S. v.
Hamburg, No. 3:14-cv-04933 (N.D. Cal. Nov. 6, 2014); Complaint, Ctr. for Food Safety, No. 3:14cv-4932 at 8
173. ELANCO, supra note 169.
174. See supra notes 79–81 and accompanying text.
175. Complaint, Humane Soc’y of the U.S., No. 3:14-cv-04933 at 16; see also Complaint, Ctr.
for Food Safety, No. 3:14-cv-4932 at 11, (“[a]lmost all ractopamine fed to cattle, pigs, and turkey
is excreted into their manure.”).
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the use of arsenicals as pesticides by the EPA, the FDA continued to
176
allow the arsenical roxarsone in poultry production. It was used to
promote rapid growth, increased weight gain, and improved feed
177
efficiency. A report estimated that in 2006, the vast majority of the
broiler chickens produced in the United States were given feed
178
containing arsenic compounds at some point in their lives.
Although no public data is available, estimates suggest that over 2
179
million pounds of roxarsone was given to chickens annually.
180
Consumer concerns led to industry pulling back on its use, and the
production of roxarsone was suspended following a 2011 FDA finding
181
However, beyond
of traces of inorganic arsenic in poultry tissue.
the direct food safety issue associated with chicken products, arsenic
has been found in poultry feathers, poultry bedding, and in the
manure that is spread on cropland—contributing to high levels of
182
arsenic in rice produced on that land.
As evidenced by the problems with the arsenic use in poultry
production, there is a persuasive argument that each of the categories
of pharmaceuticals used in the livestock industry—antimicrobials,
hormones, beta agonists, and others not addressed in this article—
176. See Susan A. Schneider, Examining Food Safety From a Food Systems Perspective:
The Need for a Holistic Approach, 2014 WISC. L. REV. 397 (2014) (“[t]he FDA’s approval led to
the widespread use of roxarsone”).
177. New Animal Drugs for Use in Animal Feeds: Roxarsone, 46 Fed. Reg. 52,330, 52,331
(Oct. 27, 1981) (affecting 21 CFR 558). [46 FR 52330-02]
178. DAVID WALLINGA, INST. FOR AGRIC. & TRADE POL’Y, PLAYING CHICKEN:
AVOIDING ARSENIC IN YOUR MEAT 13 (2006), available at http://www.iatp.org/files/
421_2_80529.pdf.
179. Id.
180. It was reported that Tyson Foods stopped using arsenicals in its chickens in 2004.
Marian Burros, Chicken with Arsenic? Is That O.K.?, N.Y. TIMES (Apr. 5, 2006),
http://www.nytimes.com/2006/04/05/dining/05well.html. Perdue said it stopped using arsenicals
in 2007. Darryl Fears, Maryland Set To Ban Arsenic-Containing Drug in Chicken Feed, WASH.
POST (May 20, 2012), http://www.washingtonpost.com/national/health-science/maryland-set-toban-arsenic-containing-drug-in-chicken-feed/2012/05/20/gIQAFoIodU_story.html.
181. See Letter from Michael Taylor, Deputy Comm’r for Foods & Veterinary Medicine, to
Paige M. Tomaselli, Staff Attorney, Ctr. for Food Safety, and David Wallinga, Director, Food &
Health Division of Inst. for Agr. and Trade Pol’y 5 (Sept. 30, 2013), available at
http://www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/UC
M370570.pdf (denying the Center for Food Safety petition).
182. See Susan A. Schneider, Examining Food Safety From a Food Systems Perspective: The
Need for a Holistic Approach, 2014 WISC. L. REV. 397 (2014) (citing Fu-Min Wang, Zhang-Liu
Chen, Lu Zhang, Yan-Ling Gao, & Yong-Xue Sun, Arsenic Uptake and Accumulation in Rice
(Oryza sativa L.) at Different Growth Stages Following Soil Incorporation of Roxarsone and
Arsanilic Acid, 285 PLANT & SOIL 359 (July 2006) (concluding that rice could accumulate
arsenic “from contaminated soil (roxarsone or arsanilic acid), which may be transferred to
human beings via the food chain”)).

11-Schneider_Final (Do Not Delete)

254

DUKE ENVIRONMENTAL LAW & POLICY FORUM

8/17/2015 5:20 PM

[Vol. XXV:227

should be more carefully reviewed for the environmental impacts
associated with their use. Numerous scientific studies performed on
each of the individual categories and/or on individual pharmaceuticals
183
support this argument.
Adverse environmental impacts are not
being adequately considered in our evaluation and approval of the
184
use of these drugs.
There is an even more persuasive argument that we have no
concept, indeed no way to adequately measure, the cumulative
impact of the millions of pounds of different drugs used in the
livestock industry. Much of those drugs are then excreted in the 1.1
billion tons of manure produced each year.
IV. THE REGULATION OF DRUGS ADMINISTERED TO LIVESTOCK
The United States Department of Agriculture is the federal
agency involved in most matters involving livestock production,
185
including the prevention of livestock disease and the regulation of
186
livestock markets.
The USDA is also responsible for the labeling
187
and safety regulations applicable to most meat products.
Nevertheless, as described below, the regulation of animal drugs is
controlled by the FDA.
A. The Regulation of Animal Drugs Under the Food, Drug, and
Cosmetic Act
The Food, Drug, and Cosmetic Act (FDCA) governs the
approval of animal drugs and gives regulatory authority to the
188
Secretary of the Department of Health and Human Services (HHS).
183. See, e.g., Alistair B. A. Boxall et al., Are Veterinary Medicines Causing Environmental
Risks?, 37 ENVTL. SCI. & TECH. 286A (2003) (discussing the likelihood of various veterinary
medicines entering into the environment, and concluding that “too little is known about the
effects of these compounds”).
184. CONERLY & CORIANO, supra note 4, at v–vi (stating that environmental impacts of
antimicrobial use in livestock are “poorly understood,” and “would benefit from further
research”).
185. The USDA Animal & Plant Health Inspection Service (APHIS) “works in a variety of
ways to protect and improve the health, quality, and marketability of our nation's animals
(including various wildlife), animal products, and veterinary biologics.” U.S. DEP’T OF AGRIC.,
Animal
&
Plant
Health
Inspection
Serv.,
http://www.aphis.usda.gov/wps/portal/
aphis/ourfocus/animalhealth (last visited Feb. 24, 2015).
186. The USDA administers the Packers and Stockyards Act, 7 U.S.C. §§ 181–229b (2012),
through the Grain Inspection and Packers and Stockyards Administration (GIPSA).
187. The USDA Food Safety and Inspection Service (FSIS) is responsible for meat
regulation as authorized under the Federal Meat Inspection Act, 21 U.S.C. §§ 601–695 (2012),
and the Poultry Products Inspection Act, 21 U.S.C. §§ 451–472.
188. The definition of “drug” contained in the statute includes “articles intended for use in
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The Secretary has delegated this authority to the Commissioner of
189
The statute provides
the Food and Drug Administration (FDA).
that a new animal drug “shall be deemed unsafe” unless the
manufacturer has obtained FDA “approval,” a “conditional
approval,” or an allowed “index listing” of the drug for use in “minor
190
species.” Animal feed that contains a new animal drug is similarly
191
regulated.
The phrase “new animal drug” is broadly defined and extends far
beyond the literal creation of a new drug. The FDCA states that
“[t]he term ‘new animal drug’ means any drug intended for use for
192
animals other than man.” The regulations clarify that it includes all
new uses for existing drugs, new combinations of drugs, the use of the
drug in a new species, and other changes in usage, composition, or
193
labeling.
The approval process for any new animal drug is outlined in
FDCA section 360b(b). The drug’s sponsor is required to submit an
application that includes “full reports of investigations which have
been made to show whether or not such drug is safe and effective for
194
use.” According to the statute, the application must also include a
“full statement of the composition” of the drug; a description of the
manufacturing process; samples of the drug, the feed it might be used
in, and edible portions of the animal to which it will be given (“as the
Secretary may require”); examples of the proposed labeling; a
description of the “practicable methods for determining the quantity,
if any, of such drug in or on food . . . because of its use;” and the
“proposed tolerance level or withdrawal period or other use
195
restrictions” necessary to render the drug’s use “safe.”
There are special provisions in the statute that exempt the

the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and
articles (other than food) intended to affect the structure or any function of the body of man or
other animals.” 21 U.S.C. § 321(g)(1)(B)–(C) (emphasis added).
189. FOOD & DRUG ADMIN., FDA STAFF MANUAL GUIDES, VOLUME II—DELEGATIONS
OF AUTHORITY: REGULATORY DELEGATIONS OF AUTHORITY TO THE COMMISSIONER FOOD
AND DRUGS 1 (2014), available at http://www.fda.gov/downloads/AboutFDA/ReportsManuals
Forms/StaffManualGuides/UCM273771.pdf.
190. 21 U.S.C. § 360b(a)(1)(A)–(C) (2012).
191. See 21 U.S.C. § 360b(a)(2)(A)(i)–(iii) (deeming animal feed containing new animal
drugs unsafe unless granted an approval, a conditioned approval, or an index listing).
192. 21 U.S.C. § 321(v) (2012).
193. 21 C.F.R. § 510.3(i) (2007).
194. 21 U.S.C. § 360b(b)(1).
195. Id.
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196

“investigational use” of drugs from this process. For some drugs, a
197
more streamlined process exists, using an “abbreviated application.”
An abbreviated application is appropriate if there has been a drug
with the same active ingredients approved previously for the same
198
use.
Support for the pharmaceutical and agricultural industries is
conspicuous throughout section 360b. Although drugs may be
considered unsafe if they do not comply with the defined approval
processes, the section includes numerous directives that prohibit the
199
agency from finding a drug unsafe. Indeed, the latest amendment to
section 360b and the animal drug review process, in general, was
200
passed as the Animal Drug Availability Act.
The Congressional
findings contained in this bill when it was first proposed, provide an
informative window into Congressional attitudes about drug use in
the livestock industry. The findings are as follows:
Congress finds that—
(1) the new animal drug approval process has been
proceeding too slowly, with the result that necessary and useful
drug therapies are being kept from the marketplace;
(2) the lack of drug approvals for new animal drugs places the
health and well-being of animals at risk;
(3) the expense and delays caused by effectiveness testing for
new animal drugs have begun to outweigh the benefits of such
testing;
(4) the overreliance on field investigations to establish the
effectiveness of new animal drugs is a primary reason the new
animal drug approval process has become so burdensome;
(5) there are not sufficient approved animal drugs available to
treat every specific disease or condition found in each species of
animal;
(6) it would benefit the public health and safety to have many
additional animal drugs reviewed and approved by the Food and

196. 21 U.S.C. §§ 360b(a)(3), (j).
197. 21 U.S.C. § 360b(b)(2). The requirements for approval under the abbreviated process
are set forth in 21 U.S.C. § 360b(n).
198. 21 U.S.C. § 360b(n)(1)(B)(i).
199. See, e.g., 21 U.S.C. § 360b(a)(4)–(6) (prohibiting the agency from finding an animal
drug unsafe for specified reasons).
200. The Animal Drug Availability Act of 1996, Pub. L. No. 104-250, 110 Stat. 3151
(codified as amended at 21 U.S.C. §§ 301, 331, 353, 354, 360b (2012)).
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Drug Administration;
(7) economic and regulatory incentives are necessary to
encourage manufacturers of animal drugs to convert unlabeled
uses of the drugs to approved, labeled uses; and
(8) it is important that the Center for Veterinary Medicine of
the Food and Drug Administration promptly implement the
recently developed mission, vision, and guiding principles of the
Center so that the Food and Drug Administration is a global leader
as a public health organization that enables the marketing of safe
and effective products.201

These findings clearly reflect Congress’ interest in expanding the
use of animal drugs in the livestock industry, although it rather
curiously justifies this interest as furthering the “the health and well202
being of animals” and “public health and safety.”
By 1995, when
these findings were reported, public health officials worldwide were
expressing serious concerns about the adverse public health
consequences associated with the overuse of antibiotics in the
203
livestock industry.
Congress’s motivations were likely expressed
more honestly in earlier findings:
In the past 15 years the animal feed industry in the United States
has been virtually revolutionized through the use of drugs and
other additives in the feed of animals. Drugs are used to promote
growth and combat disease, and as a result of the increasing use,
animals today add more meat per pound to feed in a much shorter
time than has ever been true in the past.204

Congress recognized that the livestock industry had become
dependent on using animal drugs to lower production costs. This
factor places new animal drugs in sharp contrast to human drugs. For
individuals suffering from a disease or other medical condition, the
rapid approval of a new drug to treat that condition, provided that the
drug is safe, may have a dramatic and positive impact on public
health. Streamlining the approval process can be justified for
201. S. 773, 104th Cong. § 2 (1995), available at https://www.congress.gov/104/bills/s773/
BILLS-104s773is.pdf.
202. See id. (expressing a desire to expedite and expand the approval process, and
identifying animal health and well-being and public health and safety as motivating factors).
203. For a listing of such studies, see JUDICIOUS USE, supra note 100, at 5–17.
204. H.R. REP. NO. 90-875, at 2 (1967).
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humanitarian reasons, provided it remains safe. In contrast, the
purpose of many new animal drugs is not to treat disease but to
reduce production costs. This reduction may occur through increased
feed conversion rates or through prophylactic use to allow for
increased concentration without increasing disease rates. These are
economic objectives, not public health objectives, and certainly not
animal welfare objectives. Thus, they do not deserve the same
treatment.
Despite Congress’ interest in streamlining the approval of new
animal drugs, the statute does require a showing that a new animal
205
drug be “safe and effective.”
Effectiveness refers to whether the
206
The FDCA defines “safe” as having
drug works as promised.
207
“reference to the health of man or animal.”
The notion of new animal drug safety in terms of the health of
the animal sits awkwardly next to competing economic
considerations. Many of the drugs approved are not good for the
208
animals’ health, particularly in the long run.
Rapid growth,
increased milk and egg production and related goals often run
209
completely counter to the animals’ long-term health.
For meat
producing animals, a shorter life span may actually be the economic
production goal associated with the drug. For example, steroids are
given with the express purpose of increasing the growth rate of the
210
animal.
In an animal raised for slaughter, this means an earlier
death. For product-producing animals such as dairy cows and
chickens raised for egg production, the shorter period of production
211
may be outweighed economically by increased output early in life.
205. 21 U.S.C. § 360b(b)(1)(A) (2012).
206. 21 C.F.R. § 514.4(a) (2014).
207. 21 U.S.C. § 301(u) (2012).
208. See, e.g., supra footnotes 159–176 and accompanying text (animal well being problems
resulting from the use of Zilmax (noting severe health problems associated with the use of the
drug)).
209. See, e.g., HUMANE SOC’Y OF THE U. S., AN HSUS REPORT: WELFARE ISSUES WITH
SELECTIVE BREEDING FOR RAPID GROWTH IN BROILER CHICKENS AND TURKEYS 2–3 (May
2014),
available
at
http://www.humanesociety.org/assets/pdfs/farm/welfiss_breeding_
chickens_turkeys.pdf (describing the adverse health impact of rapid growth in poultry
production and providing an extensive bibliography of animal welfare research); HUMANE
SOC’Y INT'L, AN HSI REPORT: THE WELFARE OF ANIMALS IN THE PIG INDUSTRY 6 (2014),
available
at
http://www.hsi.org/assets/pdfs/hsi-fa-white-papers/welfare_of_animals_in_the_
pig.pdf (describing animal health problems associated with industrialized hog production and
feed additives and providing an extensive bibliography of animal welfare research).
210. Steroid Hormone Implants, supra note 123.
211. For example, cows that are treated with the hormone Bovine Somatotropin (rBST)
produce more milk during peak production periods, but have other health problems including
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In determining whether the livestock drug is safe with “reference
to the health of man” the statute calls for a consideration of (1)
whether there will be drug residues found in a human food product,
and (2) if so, what level of those residues FDA determines will be
212
safe. Approval will likely involve setting a “tolerance” for the drug,
i.e., an allowed amount of drug residue found in the human food
213
products obtained from the animal that has received the drug.
Human exposure via the environment is not mentioned.
The drug may also be approved subject to a mandatory
214
“withdrawal period.” The withdrawal period is the period of time
that the drug cannot be used in order to assure compliance with the
215
set tolerance for the drug residue. For animals marketed for meat,
216
For
the withdrawal period references the time before slaughter.
other food products such as milk and eggs, it references the period of
time required between drug use and the marketing of any product
217
from the animal for human consumption.
Note that the tolerances set for various drugs are correlated with
average consumption patterns. If daily consumption values for the
218
meat decline, the FDA can and has raised the tolerances allowed.
mastitis and lameness. See generally I. R. Dohoo et. al., A Meta-Analysis Review Of The Effects
Of Recombinant Bovine Somatotropin, 67 CAN. J. VET. RES. 252 (2003), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC280709/ (presenting a meta-analysis of the effects
of rBST on various aspects of bovine health). Nonetheless, this hormone is considered safe with
reference to the animal receiving the drug. See FOOD & DRUG ADMIN., Bovine Somatotropin
(BST),
http://www.fda.gov/animalveterinary/safetyhealth/productsafetyinformation/ucm0554
35.htm (last updated July 28, 2014).
212. 21 U.S.C. § 360b(a)(6) (2012); see also, 21 U.S.C. § 360b(d)(1)(F) (allowing rejection of
any drug with a residue beyond the determined safe tolerance level).
213. 21 U.S.C. § 360b(a)(6); 21 C.F.R. § 556 (2014).
214. 21 U.S.C. § 360b(b)(1)(H); 21 C.F.R. § 514.105(a) (2014).
215. Withdrawal periods are established as part of the new drug approval process and are
published on the drug or feed label or package insert. See, 21 U.S.C. § 360b(b)(1) (requiring
person to submit the proposed withdrawal period if it is required to ensure that the proposed
use of such drug will be safe); 21 C.F.R. § 514.105 (requiring the Commissioner to forward for
publication in the Federal Register a regulation prescribing the conditions for the new animal
drug including the withdrawal period). For a helpful explanation, What are Withdrawal Times
(Periods) for Meat and Milk, and Where Can They be Found?, EXTENSION FOUND. (Sept. 6,
2007), http://www.extension.org/pages/35903/what-are-withdrawal-times-periods-for-meat-andmilk-and-where-can-they-be-found#.VPOm72PYR8w.
216. What are Withdrawal Times (Periods) for Meat and Milk, and Where Can They be
Found?, EXTENSION FOUND. (Sept. 6, 2007), http://www.extension.org/pages/35903/what-arewithdrawal-times-periods-for-meat-and-milk-and-where-can-they-be-found#.VPOm72PYR8w.
217. Id.
218. See, e.g., 76 Fed. Reg. 57,907 (Sept. 19, 2011) (to be codified at 21 C.F.R. § 556.540)
(raising the tolerance for progesterone in beef and lamb). The notice states that “Progesterone
is approved for use in subcutaneous implants used for increased rate of weight gain in suckling
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Alarmingly, there does not seem to be any practicable way for the
FDA to consider the variety of drug residues that an individual might
consume from different sources.
Section 360b authorizes the FDA to withdraw its approval of a
new animal drug “after due notice and an opportunity for hearing” if
certain conditions are met. There are six possible grounds for
withdrawal:
(1) “Experience or scientific data” shows that the drug is “unsafe
for use” under the conditions for which it was approved;
(2) “New evidence not contained in [the] application or not
available” to the agency, evaluated with the prior evidence
shows that the drug is “not shown to be safe;”
(3) On the basis of new information, together with prior
evidence, there is a “lack of substantial evidence” that the
drug will have “the effect it purports or is represented to
have;”
(4) Required patent information is not filed;
(5) The application is found to have contained an “untrue
statement of a material fact;”
(6) The applicant has made changes affecting safety or
effectiveness beyond allowed variations and not addressed in
219
a supplemental application.
There is also a provision that allows withdrawal—after due
notice and opportunity for a hearing—in cases where an applicant has
failed to comply with recordkeeping requirements, new evidence of
manufacturing problems are revealed, or new evidence of false
220
labeling is discovered.
There is also authority for an immediate suspension of approval,
but this authority is limited to the Secretary (or acting Secretary) of
Health and Human Services. Immediate suspension requires a
showing of an “imminent hazard to the health of man or of the
221
animals for which the drug is intended.” The applicant may request

beef calves and steers (21 CFR 522.1940) and in vaginal inserts used for management of the
estrous cycle in female cattle and ewes (21 CFR 529.1940)”; see also Susan A. Schneider,
Hormone Levels in Beef and Lamb: Does Anyone Care, AGRIC. L. (Oct. 15, 2011),
http://aglaw.blogspot.com/2011/10/hormone-levels-in-beef-and-lamb-does.html
(expressing
concern and surprise about the increased tolerance level for progesterone in beef and lamb).
219. 21 U.S.C. § 360b(e)(1)(A)–(F) (2012).
220. 21 U.S.C. § 360b(e)(2)(A)–(C).
221. 21 U.S.C. § 360b(e)(1).
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222

an expedited hearing.
Despite these withdrawal and suspension authorities, the FDA
has used its power sparingly, often preferring to let industry forces
223
come to bear, as with Zilmax.
Alternatively, FDA will use its
efforts to nudge the industry via guidances and voluntary
224
recommendations.
The “due process and notice of hearing” requirement associated
with withdrawal of an application may well extend to litigation
brought by a drug manufacturer that seeks to fight the withdrawal
efforts. The FDA has argued that it can be more effective, produce
results more quickly, and expend fewer resources by working
225
collaboratively with industry. This position, however, and agency’s
inaction in the face of controversial drugs, has prompted third parties
to litigate in order to force withdrawal. The case of Natural
226
Resources Defense Council, Inc. v. FDA, discussed below, serves as
one prominent example.
B. Increased Concern Over the Regulation of Antibiotics: Regulation,
Litigation, and “Judicious Use”
As already noted, there is widespread concern among health
professionals about the development of antibiotic resistant pathogens.
The extensive use of antibiotics in livestock production, particularly
of antibiotics that are important for human use, has been well
established as a contributing factor. “For over thirty years the FDA
has taken the position that the widespread use of certain antibiotics in
livestock for purposes other than disease treatment poses a threat to

222. Id.
223. See supra note 162 and accompanying text (describing the process through which
Zilmax, an FDA-approved beta agonist, was largely boycotted by the beef industry after severe
animal health problems were discovered).
224. For a current example of this approach, see infra notes 254–265 and the accompanying
text: JUDICIOUS USE, supra note 101 (attempting to convince the industry to voluntarily reduce
the use of medically important antimicrobials by explaining its concern); see also Richard A.
Merrill, Risk-Benefit Decisionmaking by the Food and Drug Administration, 45 GEO. WASH. L.
REV. 994, 1002 (1977) (explaining common criticisms that the FDA gives too much weight to
industry interests in its drug approval process).
225. E.g., FOOD & DRUG ADMIN., REPORT ON GOOD GUIDANCE PRACTICES: IMPROVING
EFFICIENCY AND TRANSPARENCY (2011), available at http://www.fda.gov/downloads/
AboutFDA/Transparency/TransparencyInitiative/UCM285124.pdf (detailing ways in which the
FDA can increase its efficiency and transparency, including making guidance documents and
recommendations more easily accessible).
226. Natural Res. Def. Council, Inc. v. FDA, 884 F. Supp. 2d 127 (S.D.N.Y. 2012)
[hereinafter Natural Res. Def. Council I].
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227

human health.”
In 1977, the FDA acted on this position, issuing notices of
withdrawal under section 360b(e)(1)(B), seeking to withdraw
approval of all subtherapeutic uses of penicillin in animal feed, and
with limited exceptions, all subtherapeutic uses of oxytetracycline and
228
chlortetracycline in animal feed.
Following the statutory
procedures for withdrawal, the notices extended the opportunity for a
229
hearing (NOOHs) to every drug manufacturer affected.
What
followed is over thirty years of industry lobbying, Congressional
interference, agency inaction, and eventually litigation—all giving rise
230
to the FDA’s current policy of “judicious use.”
Soon after the NOOHs were issued, Congress directed funds to
the National Academies of Sciences so it could conduct further
231
research on the use of antibiotics in animal feed. “The report issued
by the House Appropriations Committee included thinly veiled
suggestions that the FDA not go forward with the hearing process
232
until the research was completed.” Two years later, Congress again
expressed its interest in funding additional studies and its
discouragement of FDA action until greater certainty was
233
established.
Industry groups concurrently petitioned the FDA to withdraw
the NOOHs, but in 1983, the FDA denied their petitions and
234
reaffirmed its concerns.
Additional studies were conducted,
producing evidence of expanding antibiotic resistance and increasing
concerns about livestock production, but without specifically
providing a direct causal link between specific agricultural use and the

227. Id. at 130.
228. Penicillin-Containing Premixes: Opportunity for Hearing, 42 Fed. Reg. 43,772 (Aug.
30, 1977); Tetracycline (Chlortetracycline and Oxytetracycline) Containing Premixes:
Opportunity for Hearing, 42 Fed. Reg. 56,264, 56,266 (Oct. 21, 1977).
229. Id.
230. See Withdrawal of Notices of Opportunity for a Hearing: Penicillin and Tetracycline
Used in Animal Feed, 76 Fed. Reg. 79,697, 79,698 (Dec. 22, 2011) (recapping the FDA’s 1977
actions to withdraw uses of penicillin and tetracycline in animal feed and expressing the FDA’s
new 2011 plan to focus its energy on “the promotion of the judicious use of antimicrobials in the
interest of public health”).
231. Natural Res. Def. Council, Inc. v. FDA, 760 F.3d 151, 154 (2d Cir. 2014) [hereinafter
Natural Res. Def. Council II].
232. Id. (citing H.R. REP. NO. 95-1290, at 99 (1978)).
233. Id. at 155 (citing S. REP. NO. 97-248, at 79 (1981)).
234. Id. (citing Penicillin and Tetracycline (Chlortetracycline and Oxytetracycline) in
Animal Feeds; Denial of Petitions, 48 Fed. Reg. 4544, 4556 (Feb. 1, 1983)).
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235

specific antibiotic resistance observed.
The FDA never held the
hearings and never took any further action in its efforts to withdraw
236
the drugs noticed.
In 1999 and again in 2005, public interest groups filed petitions
with the FDA seeking withdrawal of regulatory approval for
subtherapeutic livestock use of specified antibiotics, including
237
The FDA was still not compelled to
penicillin and tetracyclines.
238
act.
In 2011, the National Resources Defense Council, with other
239
public interest organizations initiated suit. Their primary claim was
that section 360b(e)(1) “compelled the FDA to hold the hearing
proposed by the 1977 NOOHs and, if appropriate, withdraw approval
240
for the antibiotic uses the NOOHs listed.”
The FDA defended
vigorously, arguing that an alternative approach would be more
effective than seeking withdrawal. The agency alleged that the
process that was required to withdraw approval of a drug is lengthy
and costly. They also alleged that new scientific findings would be
required and that they would be forced proceed on a drug-by-drug
basis. Accordingly, the FDA argued that the alternative course of
241
action, pursuing voluntary measures, was preferable.
In December 2011, the FDA formally withdrew the 1977
242
NOOHs.
The plaintiffs amended their complaint and moved
243
forward. The district court ruled in the plaintiffs’ favor, holding that
section 360b(e) “requires the Secretary to issue notice and an
opportunity for a hearing whenever he finds that a new animal drug is
not shown to be safe. If the drug sponsor does not meet his burden of
demonstrating that the drug is safe at the hearing, the Secretary must
244
issue an order withdrawing approval of the drug.” The district court
found that the FDA’s issuance of the NOOHs in 1977 constituted a
245
finding that that drugs were not shown to be safe. It ordered FDA
235. Natural Res. Def. Council II, 760 F.3d at 155.
236. Id. at 155–56.
237. Id.
238. Id. at 156.
239. Id.
240. Id.
241. Id. at 156–57.
242. Withdrawal of Notices of Opportunity for a Hearing: Penicillin and Tetracycline Used
in Animal Feed, 76 Fed. Reg. 79,697 (Dec. 22, 2011).
243. Natural Res. Def. Council II, 760 F.3d at 157.
244. Natural Res. Def. Council I, 884 F. Supp. 2d at 143.
245. Id. at 151.
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to conduct withdrawal hearings and, unless the manufacturers could
246
rebut the finding, withdraw approval for those drug uses.
The FDA appealed the decision, and the Court of Appeals for
the Second Circuit deferred to the agency’s interpretation of the
247
statute and reversed. The Second Circuit held that the district court
erred in its reading of section 360b and that the NOOHs that were
248
issued did not constitute a finding that mandated agency action.
The majority opinion of the Second Circuit Court provides:
The statute requires the FDA to withdraw approval of an animal
drug only ‘after due notice and opportunity for hearing’ has been
afforded, and then only ‘if the Secretary finds’ that the drug is not
shown to be safe. 21 U.S.C. § 360B(e)(1). That language most
naturally refers to a finding that is issued as a result of the
hearing.249

There is a good deal of irony in this litigation. The FDA has
argued against the widespread use of subtherapeutic antibiotics in the
250
livestock industry for “over thirty years.” The plaintiffs shared the
FDA’s concerns about their use. Nevertheless, the FDA argued that
the withdrawal process would expend resources and result in costly
251
litigation.
Yet, in resisting the plaintiff’s complaint, it ended up
litigating with groups that share its concerns. In the end, it won the
252
Needless to say, this should be an
right to not take action.
unsatisfying victory in many respects.
In the midst of the litigation, the FDA issued a guidance for
industry that articulated its recommended principles for the use of
253
antibiotics in livestock production. This guidance is an embodiment
of the FDA’s preferred strategy—to work with the industry and guide
it to a better position rather than pursuing withdrawal. It is a nonbinding statement of the FDA’s favored approach to regulating the
agricultural use of antibiotics considered to be medically important to

246. Id. at 151–52.
247. Natural Res. Def. Council II, 760 F.3d at 176.
248. Id. at 174.
249. Id. at 172.
250. Natural Res. Def. Council I, 884 F. Supp. 2d at 130.
251. Natural Res. Def. Council II, 760 F.3d at 156–57.
252. Natural Res. Def. Council II, 760 F.3d at 176.
253. See generally JUDICIOUS USE, supra 100 (providing guidance on the FDA’s current
thinking on this topic).
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254

humans.
The guidance begins with an extensive description of the history
of studies and reports documenting public health concerns with
antibiotic resistance. The guidance then discusses the indirect, but
conclusively established, connection between the extensive use of
medically important antibiotics in livestock production and the
255
increasing resistance observed. It is an impressive argument against
the use of antibiotics important to human health in livestock
production.
The guidance also sets forth the FDA’s two main principles for
what it terms the “Judicious Use” of antibiotics:
Principle 1: The use of medically important antimicrobial
drugs in food-producing animals should be limited to those uses
that are considered necessary for assuring animal health.
Principle 2: The use of medically important antimicrobial
drugs in food-producing animals should be limited to those uses
that include veterinary oversight or consultation.256

There are several weaknesses associated with the FDA’s
approach. First, given the financial interests at stake, the competition
in both the livestock and the pharmaceutical industries, and the
decades of virtually unregulated antibiotic use, a voluntary approach
seems somewhat fanciful, if not naïve.
Second, the guidance contains an expansive reading of its first
principle, limiting the use of medically important drugs to “those uses
257
that are considered necessary for assuring animal health.”
The
FDA seeks to eliminate the use of antibiotics for “production
258
purposes,” i.e., growth enhancement and feed conversion.
It is
willing to allow, however, uses that are “associated with the
treatment, control, or prevention of specific diseases, including
259
administration through feed or water.”
It defines prevention as
“including the administration of an antimicrobial drug to animals,
none of which are exhibiting clinical signs of disease, in a situation

254.
255.
256.
257.
258.
259.

Id. at 3.
Id. at 5–17.
Id. at 21–22.
Id. at 21.
Id.
Id.

11-Schneider_Final (Do Not Delete)

266

DUKE ENVIRONMENTAL LAW & POLICY FORUM

8/17/2015 5:20 PM

[Vol. XXV:227

260

where disease is likely to occur if the drug is not administered.”
The problem with this approach is that the delivery of
subtherapeutic levels of antibiotics to livestock for disease prevention
is widespread and virtually inseparable from the use of those
261
antibiotics as growth promotants. The same dosage serves both
purposes, regardless of how the drug is labeled. Studies have shown
that in crowded confinement situations, livestock mortality is reduced
by the delivery of low levels of antibiotics, even though the same
262
result would likely be achieved from improved living conditions.
Thus, antibiotics can be used at subtherapeutic levels for disease
prevention purposes as a means to adjust for the stressful production
practices. Dr. Robert S. Lawrence, professor of Environmental
Health Sciences, Health Policy, and International Health at the Johns
Hopkins Bloomberg School of Public Health, explained this in his
hard-hitting criticism of the FDA guidance:
The secret to [this production system’s] success has been, in
no small part, the continuous feeding of small doses of antibiotics
to food animals throughout their lives. These drugs help animals
grow faster, and they also stave off infections linked to the squalid
conditions in which food animals are raised. The misuse of
antibiotics by the food animal industry is not just a means to make
a quick buck; misusing these drugs is the lynchpin of the industrial
model.
If antibiotics could no longer be used for disease prevention,
the food animal production industry would be forced to reform its
production practices to raise healthy animals in other ways. The
preventive use of antibiotics would no longer be “necessary.” By
eliding this fact in its guidance documents, the FDA has built
public health policy around the needs of the industry rather than
require the industry to reform itself to assure both human and

260. Id. at n. 5.
261. See, e.g., Bonne M. Marshall & Stuart B. Levy, Food Animals & Antimicrobials:
Impacts on Human Health, 24 CLIN. MICROBIOL. REV. 718, 719 (2011), available at
http://cmr.asm.org/content/24/4/718.full (explaining that some of the antibiotics administered to
feedlot animals for non-therapeutic uses are the same ones used to treat illness in both humans
and animals).
262. See, e.g., JAMES M. MACDONALD & SUN-LING WANG, U.S. DEP’T OF AGRIC , ECON.
RESEARCH SERV., SUBTHERAPEUTIC ANTIBIOTICS AND U.S. BROILER PRODUCTION 3-7
(2009)
available
at
http://ageconsearch.umn.edu/bitstream/49198/2/AAEA%20broiler
%20STA%20macdonald%20wang.pdf (discussing the studies of subtherapeutic use of
antibiotics and evaluating use in the broiler industry).
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The FDA is relying upon a veterinarian’s oversight to limit use to
situations where animals are at risk for a specific disease. However,
264
these drugs are currently sold over-the-counter. The FDA seeks to
phase-in voluntary oversight and consultation, but there is little
incentive for either the livestock industry or the pharmaceutical
industry to do so. Moreover, many veterinarians—who are less
regulated than human doctors—have close ties with or receive
265
financial benefits from the pharmaceutical industry.
Others are
266
Thus, the objective
employed by the livestock industry.
determination of “judicious use” may well be compromised. Finally,
because the “judicious use” approach only applies to antibiotics
classified as medically important, it is not likely to reduce overall
antibiotic use or their impact on the environment.
C. The Environmental Impact of Livestock Drugs
The FDCA does not make any apparent connections between
drugs fed to animals and the overall impact on the environment, e.g.,
through manure excreted. Under the terms of the statutes, the
requisite safety analysis appears only to consider the impact on
267
human consumption. However, the FDA is also subject to another
federal law, the National Environmental Policy Act of 1969
268
(NEPA). NEPA requires all federal agencies, including the FDA,
to evaluate each major agency action to determine whether it will
269
have a significant impact on the environment.

263. Robert S. Lawrence, The FDA Did Not Do Enough to Restrict Antibiotics Use in
Animals,
THE
ATLANTIC
(Apr.
16,
2012;
11:51
AM),
http://www.theatlantic.com/health/archive/2012/04/the-fda-did-not-do-enough-to-restrictantibiotics-use-in-animals/255878/.
264. JUDICIOUS USE, supra note 100, at 22.
265. Duff Wilson & Mimi Dwyer, Veterinarians Face Conflicting Allegiances to Animals,
Farmers—and Drug Companies, REUTERS (Dec. 23, 2014) http://www.reuters.com/
investigates/special-report/farmaceuticals-the-drugs-fed-to-farm-animals-and-the-risks-posedto-humans/#article-3-competing-loyalties.
266. See generally, Market Research Statistics—U.S. Veterinarians - 2013, AM. VETERINARY
MED. ASS’N, https://www.avma.org/KB/Resources/Statistics/Pages/Market-research-statisticsUS-veterinarians.aspx#categories (last visited Mar. 31, 2015) (showing 20.9 percent of
veterinarians were employed in industry jobs in 2013).
267. See generally, 21 U.S.C. § 360(b) (2012) (establishing the requirements for the
approval of new animal drugs).
268. 42 U.S.C. §§ 4321–4370 (2012).
269. 42 U.S.C. § 4332(C).
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1. An Overview of NEPA
The National Environmental Policy Act (NEPA) is designed to
encourage federal agencies to integrate environmental considerations
into their decision making by directing them to evaluate the
environmental impact of their proposed actions and, depending on
that impact, to develop reasonable alternatives that have less adverse
270
It is essentially a procedural statute. To ensure that
effects.
agencies incorporate environmental impact analysis, NEPA created
the Council on Environmental Quality (CEQ), and the CEQ
271
promulgated regulations to implement NEPA procedures.
All
federal agencies, including the FDA, are subject to these
272
regulations.
However, the FDA, like most federal agencies,
promulgated its own NEPA regulations which generally follow the
CEQ procedures but are tailored for the specific mission and
273
activities of the FDA.
The requisite NEPA process provides for an evaluation of the
274
environmental effects of any major federal action.
There are
several levels of possible analysis: a categorical exclusion
determination; the preparation of an Environmental Assessment
(EA); a Finding Of No Significant Impact (FONSI); and the
275
preparation of an Environmental Impact Statement (EIS). Despite
the concerns raised throughout out this article, the FDA regulations
confidently state that “[t]here are no categories of agency actions that
routinely significantly affect the quality of the human environment
and that therefore would ordinary require the preparation of an
276
EIS.”
Nevertheless, instructions provided to those submitting new
animal drug applications provide that drug sponsors should submit
either an EA or a claim for a categorical exclusion for certain
277
actions.
The approval of a new animal drug is included in FDA
270. See id. (requiring agencies to include in recommendations or reports on legislation and
action affecting the environment a statement covering the impact on the environment of that
action, any adverse effect, alternatives, the relationship between short-term use of the
environment and the consequences of long-term productivity, and irreversible commitments of
resources involved).
271. 40 C.F.R. §§ 1500–1518 (2014).
272. 40 C.F.R. § 1500.3.
273. 21 C.F.R. § 25 (2014).
274. 40 C.F.R. § 1500.1.
275. 40 C.F.R. § 1501.4; 21 C.F.R. § 25.15.
276. 21 C.F.R. § 25.22.
277. See
FOOD & DRUG ADMIN,
Environmental
Impact
Considerations,
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278

regulations as an action that will generally require an EA. The EA
will be prepared by the drug sponsor (the applicant) although the
FDA will be “responsible for the scope and content of EAs and may
279
include different information . . . when warranted.”
If the EA
shows that the action will not significantly affect the environment, the
280
FDA will issue a FONSI. The FONSI is a “document prepared by a
federal agency stating briefly why an action, not otherwise excluded,
will not significantly affect the human environment and for which,
281
therefore, an EIS will not be prepared.”
The drug sponsor is thus placed in a position of assessing the
environmental effects of its own request for approval. Particularly
given the financial stakes at issue, it should be no surprise to find that
EAs prepared in this situation find no adverse environmental
282
impact. If the drug sponsor were to find an adverse environmental
283
impact, the sponsor would be expected to propose an alternative.
That alternative, whether a denial of approval or a restricted
approval, would clearly work against the sponsor’s financial interests.
Nonetheless, the FDA—with limited resources and little ability to
generate its own environmental review—is dependent upon the
research submitted by the sponsor. By all appearances, the system is
designed to result in EAs that routinely support a FONSI.
If a “categorical exclusion” applies, a drug sponsor may not even
have to prepare an EA. The FDA’s website explains that this
exclusion applies to a “category of actions that the agency has
determined, based on past experience, do not individually or
284
cumulatively have a significant effect on the human environment.”
The FDA includes a number of types of new animal drug applications
in its listing of categorical exclusions, including any new animal drug
285
application “if the action does not increase the use of the drug.”
For example, the “[a]pproval of a drug for use in animal feeds if such
http://www.fda.gov/animalveterinary/developmentapprovalprocess/environmentalassessments/d
efault.htm#top (last updated Jul. 08, 2014) [hereinafter Environmental Impact Considerations].
278. 21 C.F.R. § 25.20(m).
279. 21 C.F.R. § 25.40(b).
280. 21 C.F.R. § 25.41.
281. 21 C.F.R. § 25.41(citing 40 CFR. § 1508.13).
282. See, e.g., ELANCO, supra note 169 (finding that the approval of ractopamine “would
not be expected to have any substantial adverse effect on human health or the environment”).
283. 21 C.F.R. § 25.40(a) (providing that “[i]f potentially adverse environmental impacts
are identified . . . the EA shall discuss any reasonable alternative course of action that offers less
environmental risk or that is environmentally preferable to the proposed action”).
284. Environmental Impact Considerations, supra note 277.
285. 21 C.F.R § 25.33(a).
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drug has been approved under § 514.2 or 514.9 of this chapter for
286
other uses.”
The FDA regulations provide that if an action would ordinarily
be excluded, but “extraordinary circumstances indicate that a specific
proposed action, may significantly affect the environment,” then an
287
EA will be required.
Examples include “[a]ctions for which
available data establish that, at the expected level of exposure, there
is the potential for serious harm to the environment” and “actions
that adversely affect a species or the critical habitat” of an
288
endangered species.
If the FDA anticipates that an undertaking may significantly
impact the environment, or if a project is environmentally
controversial, it may choose to prepare an EIS without having to first
289
290
seek an EA. This will rarely be the case. However, if the EA is
prepared and indicates that the environmental impact of the federal
291
action may be significant, an EIS will be prepared. Again, in part
because the applicant is responsible for preparing the EA, an EIS is
rarely indicated; and the FDA is extremely reluctant to order such an
292
analysis.
2. Applying NEPA to FDA Actions: Historical Context
When NEPA was first enacted, the FDA “initially took the
position that [NEPA] required it to consider the environmental
impact of every important action including, for example, the approval
293
of a new drug or food additive.”
As it became clear that this
286. 21 C.F.R § 25.33(a)(7).
287. 21 C.F.R. §§ 25.15, 25.21.
288. 21 C.F.R. § 25.21.
289. 21 C.F.R. §§ 21.40, 21.42 (2014).
290. See 21 C.F.R. § 25.22 (describing circumstances in which preparing an EIS without an
EA is appropriate).
291. Id.
292. FDA’s steadfast refusal to prepare an Environmental Impact Statement with regard to
the very controversial new drug application that seeks the approval of genetically engineered
salmon. See, e.g., FOOD & DRUG ADMIN., Genetically Engineered Salmon, http://www.fda.gov/
AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineered
Animals/ucm280853.htm (last visited Mar. 26, 2015); see also, HAROLD F. UPTON & TADLOCK
COWAN, CONG. RESEARCH SERV., R43518, GENETICALLY ENGINEERED SALMON (Apr. 30,
2014), available at http://www.fas.org/sgp/crs/misc/R43518.pdf (explaining the new drug
application approval process as applied to genetically engineered salmon and discussing the
NEPA review).
293. PETER BARTON HUTT, RICHARD MERRILL & LEWIS GROSSMAN, FOOD AND DRUG
LAW CASES AND MATERIALS 1309 (The Foundation Press, 4th ed. 2014). Note that one of the
authors, Peter Barton Hutt, served as Commissioner of the FDA from 1971–1975, and another,
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position was impracticable, the FDA published a Federal Register
announcement declaring that the FDCA was its sole authority for the
294
approval or rejection of any new drug or food additive. The agency
sought to “precipitate a judicial challenge that would clarify its
295
obligations under NEPA.”
As anticipated, the regulation was challenged and the agency’s
obligations were clarified. The Federal District Court for the District
of Columbia struck down the limiting regulation and held that
“NEPA requires FDA to consider environmental factors in its
decision-making process and supplements its existing authority to
permit it to act on those considerations. It permits FDA to base a
decision upon environmental factors, when balanced with other
296
relevant considerations.”
FDA revoked the contested regulation
297
soon thereafter.
Despite NEPA’s focus on systemic environmental concerns,
scholars observe that the FDA has almost never taken an action that
identified environmental effects outside the risks to health as an
298
important consideration.
And, when it has done so, it has often
been unsuccessful. When it denied a food additive petition on
environmental grounds, it was sued and the court reversed its
299
decision.
Moreover, when it attempted to stay the effect of a
regulation allowing the food additive selenium in animal feed because
300
of a potential threat to aquatic fish and wildlife, Congress forced the
301
agency to suspend the stay.
Over the years, there have been several unsuccessful attempts to
force the FDA to file an EIS. Most prominent among these were

Richard Merrill, served from 1975-1977, providing them with exceptional credibility in analyzing
the positions of the FDA during this time period. Id. at x.
294. 40 Fed. Reg. 16,662 (Apr. 14, 1975). This regulation provided that the determination
of an adverse environmental impact had “no legal or regulatory effect” and that the FDA
Commissioner was limited in his authority to apply the law set forth in the FD&CA.
295. HUTT, MERRILL & GROSSMAN, supra note 293, at 1310 (referencing the notice
published at 40 Fed. Reg. 16,662 (Apr. 14, 1975)). That notice included the statement that “[i]t
is the Commissioner’s opinion that, since the activities of the Food and Drug Administration
directly affect every person in this country, any such person has standing to obtain judicial
review of this regulation in accordance with the provisions of 5 U.S.C. § 701 et seq.”
296. Envtl. Def. Fund Inc. v. Mathews, 410 F. Supp. 336, 338 (1976).
297. 41 Fed. Reg. 21,768 (May 28, 1976).
298. HUTT, MERRILL & GROSSMAN, supra note 293, at 1311.
299. See generally Marshall Minerals, Inc. v. FDA, 661 F.2d 409 (5th Cir. 1981).
300. 58 Fed. Reg. 47,962, 47,964 (Sept. 13, 1993).
301. HUTT, MERRILL & GROSSMAN, supra note 293, at 1311 (citing 60 Fed. Reg. 53,702
(Oct. 17, 1995) and 62 Fed. Reg. 44,892 (Aug. 25, 1997)).
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efforts to object to the FDA’s approval of the genetically modified
drug recombinant bovine somanatropin (rBST or rBGH) marketed as
302
Posilac.
The plaintiffs, suing as consumers of commercially
produced milk, raised a number of challenges including the FDA’s
303
The FDA’s FONSI determination was
failure to conduct an EIS.
304
based on an EA prepared by the drug applicant, Monsanto.
The
plaintiffs claimed that environmental harms—the socioeconomic
impact on dairy farmers, health issues related to the milk produced,
305
and health issues affecting the cows—required an EIS under NEPA.
The court disagreed, holding that FDA had met all of its
306
There was no allegation or discussion of any
requirements.
environmental impact associated with the use of the drug itself.
3. Pending Challenges to FDA’s Compliance With NEPA:
Ractopamine
In November 2014, two new cases were filed against the FDA
Commissioner, Margaret Hamburg, each seeking to change the
307
FDA’s casual treatment of its obligations under NEPA. The cases
challenge the FDA’s approval of ractopamine for use in pigs, turkeys,
and cows without conducting an appropriate environmental analysis
308
under NEPA.
One case was brought by the Humane Society, United
309
Farmworkers of America, and the Animal Legal Defense Fund. It
310
311
alleges food safety risks, worker safety risks, a negative impact on
312
threatened or endangered species, and—most relevant to the
discussion herein—adverse environmental impacts from ractopamine

302. See Stauber v. Shalala, 895 F.Supp. 1178, 1182 (W.D. Wis. 1995) ([p]laintiffs challenge
defendants’ approval of intervenor-defendant Monsanto Company’s new drug application for
Posilac, a milk production-enhancing, synthetic bovine growth hormone drug.”). See discussion
of rBST, supra, note 132–140 and the accompanying text.
303. Id. at 1182.
304. Id. at 1186.
305. Id. at 1194.
306. Id. at 1194–96.
307. Complaint, Humane Soc’y, No. 3:14-cv-04933 at 30–31; Complaint, Ctr. for Food
Safety, No. 3:14-cv-4932 at 21–22.
308. Complaint, Humane Soc’y, No. 3:14-cv-04933 at 2; Complaint, Ctr. for Food Safety, No.
3:14-cv-4932 at 1.
309. Complaint, Humane Soc’y, No. 3:14-cv-04933.
310. Id. at 10–13.
311. Id. at 13–14.
312. Id. at 17–18.
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313

in livestock manure. It also challenges the approval of ractopamine
in combination with other drugs, Tylosin, Monensin, and
314
Melengestrol, citing environmental risks.
The Complaint alleges
that the FDA has never adequately assessed these impacts under
NEPA.
The other case was brought by three organizations: the Center
for Food Safety, the Center for Biological Diversity, and Sierra
315
316
Club.
It alleges food safety risks; the environmental risk of
ractopamine contaminating groundwater, streams, rivers, and other
317
surface waters; an adverse impact on threatened or endangered
318
species; and environmental risks associated with the combination
319
drugs.
Both cases cite the extensive use of ractopamine, use that far
exceeds the estimates contained in the EAs prepared by the
applicant; and both assert that the FDA has failed to adequately
320
consider the environmental impacts of such extensive use.
It
remains to be seen how the court will respond to these allegations,
but even the filings reflect a new awareness of the extent of drug use
in livestock production and the associated risk of contaminated
manure.
V. CHARTING A PATH FORWARD
The Humane Society and the Center for Food Safety litigation
may bring the issues associated with animal drug use to light, at least
with respect to the specific ractopamine usage in swine, cattle, and
turkeys. Unfortunately, the litigation will last some time and
addresses only one drug.
The FDA’s efforts to control the development of antibiotic
resistance through its “Judicious Use” policy indicates both the
agency’s interest in confronting the problem and its hesitancy to take
strong action. The FDA continues to approve new animal drugs

313. Id. at 14–17.
314. Id. at 18–24.
315. Complaint, Ctr. for Food Safety, No. 3:14-cv-4932.
316. Id. at 8–11.
317. Id. at 11–12.
318. Id. at 12.
319. Id. at 13–16.
320. See generally, Complaint, Humane Soc’y, No. 3:14-cv-04933; Complaint, Ctr. for Food
Safety, No. 3:14-cv-4932.
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321

regularly, with Freedom of Information Summaries available for
322
each drug. Yet, these summaries fail to include environmental risks
as a category of consideration, indicating that it is unlikely to change
its longstanding reliance on FONSI determinations as its sole
323
approach to NEPA.
Meanwhile, those at all ends of the livestock industry remain
locked in a competitive struggle to produce meat at the cheapest price
possible, and those in the pharmaceutical industry compete fiercely to
develop and market drugs that will assist producers in achieving that
goal. Both industries are on a new drug treadmill that rewards the
use of more powerful drugs to achieve more dramatic results. There
is no systemic analysis of the cumulative effects of these drugs’ use in
livestock production, and without that analysis, we proceed at our
peril.
The use of drugs in the livestock industry is so pervasive, so
engrained in the system, so embedded into our price structures, and
so much a part of our overall food system, that it must be asked
whether there is any way to retreat. Still, the seriousness of the risks
presented implores us to find solutions. The following proposals
provide the possibility for an interrelated way forward, employing a
range of policy tools from market-based to regulatory.
A. The Creation of a National Commission for the Evaluation of
Drug Use in the Livestock Industry
There are two overarching problems raised by the regulation of
drug use in the livestock industry. First, there is no one who is able to
see the big picture—no one who approaches the issue of livestock
production with a systemic analysis. Drugs are approved on an
individual basis with no follow-up mechanism to chart the extent of
their eventual use. There is never any consideration of cumulative
multi-drug environmental or food safety effects. Furthermore, there
is no apparent thought about the systemic impact of creating a billion
tons of contaminated manure and then applying it to cropland or
allowing it to enter waterways. Second is the closely related problem
321. Approvals are posted on the FDA website. Recent Animal Drug Approvals, FOOD &
DRUG ADMIN.
(Mar. 24, 2015),
http://www.fda.gov/AnimalVeterinary/Products/
ApprovedAnimalDrugProducts/ucm363948.htm.
322. See, e.g., FOOD & DRUG ADMIN., FREEDOM OF INFORMATION SUMMARY
SUPPLEMENTAL NEW ANIMAL DRUG APPLICATION: ZILMAX PLUS RUMENSIN PLUS
TYLAN PLUS MGA (2015), available at http://www.fda.gov/downloads/AnimalVeterinary/
Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM433793.pdf.
323. Id.
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of secrecy. Even the agency charged with regulating animal drugs
does not have access to how or where they are being used.
A bipartisan commission should be created to accurately
evaluate the full extent of drug use in the livestock industry; the
cumulative impact of this drug use; the public health and animal
welfare effects; and the full range of environmental effects. The
commission would further explore public and private pressures placed
on FDA regulators; efforts to influence research to produce results in
line with industry objectives; and efforts to prevent transparency in
agricultural practices. The commission would be charged with
reporting its findings to Congress, the President, and the public.
Based on its findings, the commission would make recommendations
to the relevant agencies involved, and to Congress if additional
legislation were proposed. This commission would have wide
authorities to obtain otherwise privileged information and to consult
widely with a full range of affected parties.
B. The Expanded Use of Certification Programs for Meat Produced
Without Drugs
There are producers and retailers who would like to decrease or
eliminate livestock drugs in their operations, but the current market
structure places them at a disadvantage. If all meat is the same, cost
of production is the only driver for economic success. Similarly,
consumers who are concerned about drug use in livestock production
may feel they have few options. Systems for verifiable labeling serve
both interests.
Public and private certification programs should be encouraged,
assisting the industry with a value-added approach to minimizing drug
use. This has already begun, with successful “raised without
324
antibiotics” market initiatives and associated certifications.
The
USDA currently grades meat and poultry products and verifies some
325
production practices, but enhanced efforts should be made to

324. As a current example, the “Never-Ever Process Verified Program” certifies that
livestock is raised without antibiotics administered in any form; that is raised without growth
hormones or other synthetic growth promotants (including natural or synthetic, estrus
suppressants, beta agonists, or other drugs to promote or impact growth); and, that it is raised
without being fed any mammalian and avian byproducts. See, U.S. DEP’T OF AGRIC., NEVER
EVER
3
(NE3)
(2009),
available
at
http://www.ams.usda.gov/AMSv1.0/getfile?
dDocName=STELPRDC5066028.
325. E.g., U.S. DEP’T OF AGRIC., Grading, Certification, and Verification (Jan. 14, 2013),
http://www.ams.usda.gov/AMSv1.0/ams.fetchTemplateData.do?template=TemplateA&navID=
GradingCertificationandVerification&leftNav=GradingCertificationandVerification&page=Gr
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develop a range of certification opportunities for drug-free
production practices. The USDA should actively promote these
efforts and encourage producers and consumers to move toward the
reduced use of livestock drugs. Incentive programs to assist
producers in the transition toward drug-free practices should be
established.
C. A Commitment to Transparency Throughout the Food System
Under the current regulatory system for drugs used in livestock
production, most drugs are purchased over-the-counter or in
proprietary feed mixes. In this system the chemical composition of
drugs and feed additives may be protected by patents and
trademarks, and even regulating agencies may be unaware of industry
practices. Consumers are likely to be unaware of drug use, drug
residues, and potential contamination issues. The following steps
would help to ensure a more transparent system.
The Department of Health and Human Services (incorporating
the FDA and the CDC) should be allowed access to accurate
information about what drugs are being used. This includes
information about on-farm use, specific-species use, off-label use, and
information about adverse impacts.
This would require recategorizing livestock drugs or establishing a new reporting system
for livestock drug use.
Information on drug use that is site-specific should be available
to EPA, state environmental agencies, local and tribal governments,
and to environmental researchers in order for the cumulative
environmental and public health effects of use to be assessed. This
will not only alert agencies and governments to what is being used in
their area, it will also assist in identifying the source of any
contamination that may occur—be it from human or animal drug use.
Public funding and assistance should be provided to states, tribes,
and communities for testing water and soil samples for drug residues.
This will allow these communities to build a database of information
on drug residue contamination patterns from all uses.
Additionally, meat labeling should either include mandatory
reference to production practices involving significant drug use and/or
information on drug use should be available to consumers on product
websites. Relevant government agencies including the FDA and the

adingCertificationAndVerification&acct=AMSPW.
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USDA should have dedicated consumer awareness programs to
provide interested consumers with information about the food they
eat and how it has been produced. The agencies should combat
efforts to limit transparency, encouraging disclosures rather than
protecting industry secrecy.
USDA residue testing should be increased, with results made
available to the public. In addition, regular residue testing by meat
processors should be required in conjunction with the pathogen
testing now conducted under a processor’s requisite HACCP system.
The only exception should be for processors who obtain certifications
326
that drugs were not used in production.
D. Requirements to Protect the Integrity of Veterinarians, Veterinary
Schools, and Veterinary Associations
Veterinarians are critical to FDA’s “judicious use” approach to
the use of antibiotics. Yet, currently, there is no public disclosure
required for any of their financial connections with the
pharmaceutical industry. Similarly, some veterinarians may be
financially dependent upon a livestock integrator who seeks medical
authority for drug use. Regulations should be put in place to protect
the integrity of the veterinary profession.
E. Increased Public Funding for Research and Higher Standards for
University Agricultural Research
Much of the animal science research now undertaken at our
public land grant universities is funded by private companies with a
vested interest in the outcome of the studies. Unfortunately, this can
and often does influence the type of research that is done. This
funding system can also taint research results, as reported in the
Chronicle of Higher Education in an article about Zilmax research:
Scores of animal scientists employed by public universities
have helped pharmaceutical companies persuade farmers and
ranchers to use antibiotics, hormones, and drugs like Zilmax to
make their cattle grow bigger ever faster. . . .
It’s been a profitable venture for the drug companies, as well
as for the professors and their universities. Agriculture schools
326. HACCP refers to the Hazard Analysis Critical Control Points system of testing for
and controlling pathogen contamination in meat processing. See generally HAACP. U.S. DEP’T
OF AGRIC. (Mar. 24,
2015), http://www.fsis.usda.gov/wps/portal/fsis/topics/regulatorycompliance/haccp.
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increasingly depend on the industry for research grants . . . [a]nd
many professors now add to their personal bank accounts by
working for the companies as consultants and speakers. More than
two-thirds of animal scientists reported in a 2005 survey that they
had received money from industry in the previous five years.327

Unfortunately, schools of agriculture have “largely rejected
328
critics’ concerns about industry cash.”
It is reported that few
agriculture school administrators are willing to set limits on faculty
who accept corporate money, and confidentiality rules may prevent
329
public disclosure.
Objective research is critical to good regulatory and policy
decision making. The connection between researchers (who study the
impact of new technologies) and the manufacturers (who stand to
benefit from the sale of those products) must be dismantled. Public
funding should be restored to prior levels, and agriculture
departments at our universities should ensure that their policies
demand objectivity and integrity from their professors. Strict conflict
of interest provisions and limitations on private compensation should
be in place at all research institutions.
F. Increased Regulation
The interpretation of the “safe and effective” test that is used to
approve new animal drugs must be expanded to include an analysis of
safety that incorporates environmental considerations and cumulative
effects. We must develop a more systemic, holistic approach to
regulating our food system. Mechanisms for tracking drug use on the
farm and in all animal facilities must be in place so that the agencies
can accurately evaluate the extent of use and the environmental
consequences of that use. In addition, the FDA must be adequately
funded so that it can perform its own environmental assessments of
the impact of new drug approvals, perhaps in partnership with the
EPA and publicly funded research entities.
Drugs deemed critical for human medical use should be banned
in livestock production absent extraordinary circumstances, such as a
327. Melody Petersen, As Beef Cattle Become Behemoths, Who Are Animal Scientists
Serving?, CHRON. OF HIGHER EDUC. (Apr. 15, 2012), http://chronicle.com/article/As-BeefCattle-Become/131480/ (criticizing the influence of industry funding on animal science
research).
328. Id.
329. Id.
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major livestock epidemic. Drug uses that increase animal suffering in
any way should similarly be prohibited. Relatedly, new drug
approvals should be guided by a safety analysis that truly includes
consideration of the safety of the animal to which the drug is
administered.
Companies and persons found to have used a drug inconsistently
with label directions and approved usage should bear financial
responsibility for remediating drug contamination of soil and water.
Finally, the associated adverse effects on the environment should be
assessed on companies marketing the drug for farm use and on
anyone found to have not used the drug consistent with label
directions and approved dosage.
G. Campaign Finance Reform and Restrictions on Industry Lobbying
The lack of regulation of drugs in the livestock industry is all too
often traced back to Congressional pressure on an under-resourced
agency.
Intimately intertwined with campaign funding, this
Congressional pressure all too often influences policies that should be
decided on the merits. As noted herein, efforts to prevent limitations
on antibiotic use in livestock production have been obvious and
largely successful, despite increasing public health concerns
worldwide. As long as our political system is influenced most by
those with the most funds to invest in it, it will be extremely difficult
to enact thoughtful, objective public policy.
VI. CONCLUSION: A NEW VIEW OF OUR FOOD SYSTEM
The industrialization of our food production systems—namely
the use of a manufacturing model for the production of food—has led
many to forget that food is not just another manufactured item. Our
food begins as a living thing, whether plant or animal, and it grows
through natural biological processes. One process affects another,
and each interacts with the environment.
Yet, our regulatory systems treat each aspect as if it were in
isolation. Our system for regulating drug use seems to discount the
fact that what an animal ingests will be present in that animal’s
system, in the products of that animal, and in the manure and urine it
excretes. It ignores the fact that all of the drugs used may have a
cumulative, even a synergistic effect, that far exceeds the analysis of
any individual drug. Our food system is just what it claims to be—a
system—and it is a system that is deeply intertwined with and
dependent upon the environment. We need to stop regulating
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individual components without regard for the whole.
In the end, consumers have a critical role to play. Michael
Pollan’s oft-quoted comment about “eating as a political act,” an
extension of Wendell Berry’s saying that “eating is an agricultural
330
act,” remains the most realistic avenue for a change.
Ultimately, it may be consumers’ increasing interest in their
food—where it comes from and how it was produced—that has the
most impact on our future. Industry responds to the marketplace.
331
Whether it is Chiplotle marketing its “food with integrity;” Tyson
332
Foods essentially halting the use of Zilmax throughout the industry;
333
or efforts in the poultry industry to eliminate the use of antibiotics;
companies react to consumer interests. Assuring that consumers have
the information they want and need will go a long way towards
improving the food system upon which we all depend.

330. See Joe Fassler, The Wendell Berry Sentence That Inspired Michael Pollan's Food
Obsession, THE ATLANTIC (Apr. 13, 2013), http://www.theatlantic.com/entertainment/
archive/2013/04/the-wendell-berry-sentence-that-inspired-michael-pollans-foodobsession/275209/ (discussing how connecting the dots between the farm and the plate leads to
more change in the industry).
331. What is Food with Integrity?, CHIPOTLE, http://www.chipotle.com/en-US/fwi/fwi.aspx
(last visited Mar. 28, 2015).
332. Lost Hooves, supra note 160.
333. David Kesmodel et al., Meat Companies Go Antibiotics-Free as More Consumers
Demand It, WALL ST. J. (Nov. 3, 2014), http://www.wsj.com/articles/meat-companies-goantibiotics-free-as-more-consumers-demand-it-1415071802.

